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Colorectal cancer (CRC) is one of the most common forms of cancer in both men and 
women worldwide.(1) The incidence of CRC is highest in Western countries, were the 
lifetime risk of developing colorectal cancer is around 5% and most patients are >60 
years of age at the time of diagnosis.(1, 2) In the Netherlands, almost 15.000 new cases 
were diagnosed in 2017.(3) Despite the improvement of treatment, 5-year survival of 
CRC is still only 65%. Survival strongly depends on the stage in which colorectal cancer 
was found, decreasing from 90% in patients with stage I CRC to approximately 10% in 
patients with stage IV CRC.(4) 
 
Colorectal cancer prevention 
CRC develops from a precancerous lesion; an adenoma. Development from an adenoma 
into CRC (adenoma-carcinoma sequence) can take many years.(5-7) Therefore, CRC can 
be prevented by timely removal of adenomas.(8) Since CRC poses an important health 
burden, has markedly better survival when it is diagnosed at an early stage, and even has 
a recognizable premalignant lesion which can be removed during colonoscopy, it is an 
excellent candidate for population based screening.(9) In fact, in many countries 
population based screening for CRC has been implemented.(10) In the Netherlands, a 
population based screening program using fecal immunohistochemical test (FIT) for all 
individuals from 55-75 years of age started in 2014.(11) 
 
Lynch syndrome 
A small part of all CRCs is caused by a hereditary predisposition. In these patients, CRC 
often develops at a younger age. Lynch syndrome (LS) is the most common hereditary 
CRC predisposition, accounting for 2-3% of all CRC cases.(12-15) The first report of LS 
dates back to 1895, when Warthin described the family of his seamstress, in which most 
family members died from CRC. This hereditary predisposition to CRC was later named 
Lynch syndrome, after dr. Henry T. Lynch described more families with a similar 
phenotype. It would take years until the underlying genetic causes were found.(16) 
 
LS is caused by autosomal dominant mutations in the mismatch repair (MMR) genes 
MLH1, MSH2, MSH6 or PMS2.(17-20) Additionally, although it is not a MMR gene, 
deletions of the 3’region of the EPCAM gene can also cause LS, due to hypermethylation 
and thereby silencing of the adjacent MSH2 gene.(21) Similarly, although rare, germline 
hypermethylation of the promoter region of the MLH1 or MSH2 gene have been 
described in LS patients.(21) 
 
The MMR genes are essential for the detection and consequent correction of 
mismatches that arise during DNA replication. Furthermore, the MMR genes play an 
important role in the induction of apoptosis in response to certain cytotoxic agents.(22, 
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23) In LS patients a mutant allele of one of the MMR genes is present in all cells. If a 
second (somatic) mutation occurs in the wild type allele, mismatches cannot be repaired, 
and cancer may develop. 
 
LS patients have a lifetime risk of up to 74% of developing CRC. The cumulative risk is 
highly dependent on the gene involved, with lowest risk for PMS2 and MSH6 mutation 
carriers and the highest risk for MLH1 and MSH2 mutation carriers.(24-29) Especially in 
MLH1 and MSH2 mutation carriers, CRC often develops before the age of 50.(30-32) 
Furthermore, LS patients are also at risk of developing extra-colonic cancers, in particular 
endometrial cancer (EC) in women with a lifetime risk of 12-54%.(24-29) The risk of other 
types of cancer, such as ovarian, gastric, urinary tract and small intestinal cancer is also 
increased in LS patients.(24-29) 
 
CRC morbidity and mortality in LS patients can be significantly reduced by intensive 
colonoscopy surveillance from a young age.(33-36) In these patients, colonoscopy with 
removal of adenomas is recommended every 2 years starting from age 25 or 2-5 years 
before the youngest CRC diagnose if a family member was diagnosed under 25 years of 
age.(25, 37, 38) In case CRC develops, (sub)total colectomy with ileorectal anastomosis 
should be considered instead of segmental colectomy, to reduce the risk of developing 
metachronous CRC. In a meta-analysis, metachronous CRC was found in 22,8% of the 
patients who underwent segmental colectomy despite adequate postoperative 
colonoscopy surveillance compared to 6% of the patients with an extended 
colectomy.(39) However, a decision analysis model showed that the overall gain in life 
expectancy for patients undergoing subtotal colectomy compared with hemicolectomy 
decreased with age from 2,3 years for LS patients aged 27 years to 1 year for LS patients 
aged 47 years and only 0,3 year for LS patients aged 67 years.(40) Therefore, in older 
patients segmental colectomy is probably appropriate. The benefits and increased 
morbidity after subtotal colectomy should be discussed with each LS patient developing 
CRC. After surgery, surveillance of the residual colon is still indicated. 
 
For women with LS, gynecologic surveillance by transvaginal ultrasound, endometrial 
sampling and CA-125 tumor marker testing, is also recommended, although there is little 
evidence for the yield of this type of screening.(25, 33, 34, 37, 41-44) Women with LS can 
also opt for prophylactic hysterectomy and salpingo-oophorectomy after childbearing is 
completed to prevent the development of gynecological cancers.(25, 37, 38, 45) 
However, in order for LS patients to benefit from surveillance programs, they first have 
to be identified. Once a LS patients is identified, presymptomatic testing becomes 
available for family members, allowing relatives carrying the same mutation to start 
surveillance as well. 
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Identification of LS patients 
As LS is an autosomal dominant predisposition, family history can be used to identify LS 
patients. The Amsterdam criteria were established in 1990 to select CRC patients suspect 
for having LS based on the age of CRC diagnosis and family history of CRC.(46) An 
updated version, the Amsterdam II criteria, also include extra-colonic cancers (Table 
1).(47) Nevertheless, around 60% of the LS families do not fulfill these criteria.(48) 
 
In 1997 the Bethesda guidelines were introduced(49) followed by the revised Bethesda 
guidelines in 2004, which have a higher sensitivity than the Amsterdam criteria (Table 
2).(50) However, the revised Bethesda guidelines still have limited sensitivity and are not 
well implemented in clinical practice.(51-54) 
 
*LS-associated tumors: CRC, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, 
brain, sebaceous gland and small bowel cancer. 
**Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring 
differentiation, or medullary growth pattern. 
Over the years, prediction models based on personal cancer history and family history 
have also been developed. Some of these models, the PREMM5, MMRpredict and 
MMRpro model, are available as free web-based prediction models.(55-57) Upon 
entering patient and family data, the probability of carrying a MMR mutation is 
calculated. Several studies have shown adequate performance of these prediction 
models in identifying LS patients among CRC patients.(13, 58-63) An advantage of the 
PREMM5 and MMRpro model is the fact that they can not only be used for CRC patients, 
but also for patients with other types of cancer or even healthy individuals. The MMRpro 
model however, needs extensive input including current ages of all family members, 
Table 1. The Amsterdam II criteria (49) 
• At least 3 relatives with any LS-associated cancers 
• One should be a first-degree relative of the other two 
• At least two successive generations should be affected 
• At least one patient should be diagnosed before age 50 
• Familial adenomatous polyposis should be exclude in the CRC case(s), if any 
• Tumors should be verified by pathological examination 
Table 2. The revised Bethesda guidelines (50) 
• CRC diagnosed <50 years of age 
• Synchronous or metachronous LS-associated tumors* regardless of age 
• CRC with specific histology** <60 years of age 
• CRC diagnosed in one or more first-degree relatives with a LS-associated tumor,  
with one <50 years of age 
• CRC diagnosed in two or more first- or second-degree relatives with a LS-associated tumor,   
regardless of age 
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which is less likely to be available or at least time consuming in clinical practice. Current 
guidelines recommend the use of prediction models as part of the strategy to identify 
MMR mutation carriers among patients with CRC. All methods to identify LS patients 
based on family history lack sensitivity especially for MSH6 and PMS2 mutation carriers, 
due to the lower penetrance. Another disadvantage of these strategies is the fact that 
family history is often unreliable or unavailable, limiting the yield of prediction models 
based on family history.(64-66) 
 
Molecular diagnostics to identify LS patients 
A method not involving family history to identify patients who are likely to have LS is 
based on molecular diagnostics on tumor tissue. Tumors caused by LS are characterized 
by MMR deficiency and show microsatellite instability (MSI) and loss of MMR protein 
expression.(67) Microsatellites are stretches of DNA consisting of small repetitive 
sequences of nucleotides, for example mononucleotide or dinucleotide repeats. In case 
of MMR deficiency, these sequences are prone to errors in DNA replication and 
therefore will become unstable resulting in microsatellites of different sizes. A pentaplex 
panel of five mononucleotide repeats is recommended for MSI analysis.(67) If at least 
two out of these five repeats show MSI, MMR deficiency in the tumor is assumed. 
Approximately 85% of the tumors from LS patients show MSI.(68-71) Patients with 
tumors displaying MSI have a better prognosis and survival than those without MMR 
deficiency.(69, 72) Also, for patients with tumors showing MSI, 5FU chemotherapy is not 
beneficial.(73-75) More recent data also suggests a role of immune checkpoint inhibitors 
as a therapy for MMR deficient tumors regardless of the organ involved.(76) Therefore, 
MSI analysis will be increasingly performed as a prognostic marker as well as for 
treatment options. 
 
The second hallmark of MMR deficiency in LS associated tumors is loss of MMR 
protein(s) at immunohistochemistry (IHC).(67) An advantage of IHC analysis is that loss of 
a MMR protein not only shows MMR deficiency, but directly indicates the affected MMR 
protein. In tumors from MSH6 or PMS2 germline mutation carriers, loss of expression of 
the corresponding protein is seen in tumor cells. In case of a germline MLH1 mutation, 
tumor cells show absent staining for MLH1 as well as PMS2 protein, since loss of MLH1 
protein leads to destabilization of the PMS2 protein. Similarly, in tumors from MSH2 
mutation carriers, expression of both MSH2 and MSH6 protein is lost. Therefore, loss of a 
specific MMR protein or a combination of MMR proteins allows for targeted germline 
mutation analysis of the corresponding MMR gene. Sensitivity of IHC analysis is found to 
be around 83%.(71, 77) Some pathogenic mutations still allow protein formation, while 
the protein does not function properly. In such cases, there will be no loss of MMR 
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protein in tumor cells, even though the tumor is MMR deficient.(67) Such false negative 
results are most frequent in missense MSH6 mutations. 
 
While MMR deficiency in a tumor is suggestive for an underlying germline MMR 
mutation, it can also be seen in sporadic tumors. In sporadic tumors, MMR deficiency 
can be caused by epigenetic silencing of MLH1 due to hypermethylation of the MLH1 
promoter.(67) Furthermore, MMR deficiency can be caused by two somatic MMR 
mutations, or one somatic MMR mutation combined with loss of heterozygosity.(78, 79) 
 
Around 12-20% of all CRC show MMR deficiency.(12, 80-82) In cases with loss of MLH1 
protein expression, MLH1 promoter hypermethylation analysis can distinguish sporadic 
MMR deficient tumors from tumors likely caused by LS.(67) In cases without MLH1 
hypermethylation and in cases with loss of MSH2, MSH6 or PMS2 protein without a 
germline MMR mutation found, somatic mutation analysis can often clarify the cause of 
MMR deficiency. Somatic mutation analysis identifies two sporadic hits in >50% of the 
patients with a MMR deficient tumor in whom no germline MMR mutation is found.(78, 
79) 
 
The revised Bethesda guidelines were previously used to select patients in whom 
molecular diagnostics for LS should be performed.(50) Since these guidelines are 
underutilized in clinical practice leading to underdiagnosis of LS, routine molecular 
diagnostics for LS was proposed for CRC and EC patients.(54) In the Netherlands, the 
MIPA criteria were established, which entailed that pathologists could select CRC 
patients for MSI testing in case of 1) CRC < 50 years of age, 2) second CRC, 3) CRC and 
another LS-associated cancer, or 4) a colorectal adenoma with high grade dysplasia <40 
years of age.(83) A multicenter study showed a high yield of routine screening for LS by 
MSI and IHC analysis in CRC and EC patients up to 70 years of age.(84, 85) Some even 
recommend universal screening of all CRC patients without an age cut-off. Off course, 
the more extensive the screening is, the more LS patients will be identified. However, 
cost-effectiveness should also be established before implementation of screening 
strategies. 
 
Germline mutation analysis 
A definite diagnosis of LS is made by the identification of a pathogenic germline MMR 
mutation. Once a pathogenic germline mutation is identified in a family, 
(presymptomatic) testing of relatives also allows relatives carrying the same mutation to 
enroll in surveillance programs. In some cases however, a variant of unknown 
significance (VUS) is found and the diagnosis remains uncertain. Over recent years tumor 
testing for LS and consecutive germline mutation analysis for LS is increasingly 
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performed. This will not only increase the number of LS diagnoses, but likely will also 
lead to more patients in whom a VUS in one of the MMR genes is found. Also, in the 
current era where whole exome sequencing is increasingly used for all kinds of 
conditions, more and more VUS are likely to be found in MMR genes. This implies the 
need for assays to determine pathogenicity of such VUS. Several functional assays have 
been developed for VUS in MMR genes.(86-89) 
 
Surveillance programs for Lynch syndrome 
After identification of LS patients, they are offered to enroll in a surveillance program, 
which can significantly reduce morbidity and mortality.(33-36) The goal of such intensive 
surveillance programs is of course the prevention or early detection of cancer. Although 
germline mutations in the different MMR genes result in different cancer risks, 
surveillance programs for LS are currently not tailored to the gene involved (Table 3). 
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Lynch syndrome is the most common hereditary predisposition for colorectal cancer, 
accounting for 2-3% of all colorectal cancer cases. Furthermore, individuals with Lynch 
syndrome are at increased risk of developing extracolonic cancers, in particular 
endometrial cancer in women. The syndrome is caused by autosomal dominant 
mutations in the mismatch repair genes MLH1, MSH2, MSH6 or PMS2, or by deletions of 
the 3’region of the EPCAM gene. The identification of individuals with Lynch syndrome is 
of great importance, since surveillance programs can significantly reduce their cancer 
morbidity and mortality. 
 
This thesis focusses on the identification of Lynch syndrome patients, the interpretation 
of variants found by germline mutation analysis, and the yield of colorectal cancer 
surveillance for Lynch syndrome patients. The introduction in chapter 1 includes an 
overview of these different aspects of Lynch syndrome. 
 
The aim of the first part of this thesis was to determine ways in which the identification 
of Lynch syndrome patients can be improved. In chapter 3, the diagnostic yield of two 
prediction models for Lynch syndrome (MMRpredict and PREMM5) are reviewed in a 
cohort of colorectal cancer patients and an extended version of the PREMM5 model is 
proposed. Chapter 4 and 5 assess the cost-effectiveness of routine screening for Lynch 
syndrome by molecular diagnostics in patients with colorectal cancer or endometrial 
cancer up to 70 years of age. Routine molecular screening for Lynch syndrome in 
adenomas (a precursor lesion of colorectal cancer) may have a higher benefit than 
screening among cancer patients, since colorectal cancer can still be prevented in these 
patients. Therefore, chapter 6 evaluates the yield of screening for Lynch syndrome in 
adenoma patients within the national FIT-based screening program for colorectal cancer. 
 
A definite diagnosis of Lynch syndrome can be made once a pathogenic germline 
mutation is identified. In some cases, a variant of unknown significance is found and the 
diagnosis remains uncertain. In chapter 7 and 8 an assay for variants of unknown 
significance in MLH1, MSH2 and MSH6 is evaluated and several variants in these genes 
are analyzed. 
 
Although the cancer risk in Lynch syndrome patients is highly dependent on the gene 
involved, surveillance programs are currently not tailored based on genotype. Therefore, 
chapter 9 evaluates the effectiveness of colonoscopy surveillance in MLH1, MSH2, MSH6 
and PMS2 mutation carriers. 
 
Finally, chapter 10 discusses the results of this thesis in perspective of the current 
guidelines and clinical practice. 
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ABSTRACT 
 
Background Until recently, no prediction models for Lynch syndrome (LS) had been 
validated for PMS2 mutation carriers. We aimed to evaluate MMRpredict and PREMM5 
in a clinical cohort and for PMS2 mutation carriers specifically.  
Methods In a retrospective, clinic-based cohort we calculated predictions for LS 
according to MMRpredict and PREMM5. The area under the operator receiving 
characteristic curve (AUC) was compared between MMRpredict and PREMM5 for LS 
patients in general and for different LS genes specifically. 
Results Of 734 index patients, 83 (11%) were diagnosed with LS; 23 MLH1, 17 MSH2, 31 
MSH6 and 12 PMS2 mutation carriers. Both prediction models performed well for MLH1 
and MSH2 (AUC 0.80 and 0.83 for PREMM5 and 0.79 for MMRpredict) and fair for MSH6 
mutation carriers (0.69 for PREMM5 and 0.66 for MMRpredict). MMRpredict performed 
fair for PMS2 mutation carriers (AUC 0.72), while PREMM5 failed to discriminate PMS2 
mutation carriers from non-mutation carriers (AUC 0.51). The only statistically significant 
difference between PMS2 mutation carriers and non-mutation carriers was proximal 
location of colorectal cancer (77% vs. 28%, p<0.001). Adding location of colorectal cancer 
to PREMM5 considerably improved the models performance for PMS2 mutation carriers 
(AUC 0.77) and overall (AUC 0.81 vs. 0.72). We validated these results in an external 
cohort of 376 colorectal cancer patients, including 158 LS patients. 
Conclusion MMRpredict and PREMM5 cannot adequately identify PMS2 mutation 
carriers. Adding location of colorectal cancer to PREMM5 may improve the performance 
of this model, which should be validated in larger cohorts. 
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INTRODUCTION 
 
Lynch syndrome (LS) is a hereditary predisposition to colorectal cancer, endometrial 
cancer and other extra-colonic cancers at a young age.(1, 2) Morbidity and mortality of 
LS carriers can be significantly reduced by surveillance programs.(3-5) Therefore 
identifying LS carriers is of great importance. 
 
LS is caused by a germline mutation in one of the mismatch repair (MMR) genes MLH1, 
MSH2, MSH6 or PMS2, or in the 3’ end of the EPCAM gene and consequent 
hypermethylation of the MSH2 promoter region.(6-10) As a result, tumours in LS patients 
are characterized by microsatellite instability (MSI) and by loss of MMR protein 
expression in immunohistochemistry (IHC).(11-13) Analysis of MSI and IHC, combined 
with MLH1 promoter methylation analysis to exclude sporadic MMR deficient tumours, 
are used to identify patients with tumours likely caused by LS.(13) A definite diagnosis of 
LS is made when a pathogenic germline mutation is found. 
 
The revised Bethesda guidelines were based on a set of diagnostic criteria to select 
patients eligible for LS screening in tumour tissue. However, due to limited sensitivity, 
many LS patients will likely be missed by these guidelines.(14-17) Several prediction 
models, such as MMRpro, MMRpredict and PREMM5 have also been developed to 
calculate an individual’s probability of carrying a germline MMR mutation.(18-20) These 
models could aid in the selection of patients at high risk of having LS, for tumour analysis 
or direct germline mutation analysis. MMRpro is less useful in clinical practice since 
detailed information of all relatives is needed as input for the model.(19) However, 
MMRpredict and PREMM1,2,6 (a previous version of the newly developed PREMM5 
model) both performed well in previous evaluations.(21-27) An advantage of PREMM5 is 
that it can also be used for individuals with extracolonic malignancies and healthy 
individuals, as opposed to MMRpredict, which can only be used for CRC patients. Until 
recently, all prediction models for LS were developed with cohorts of patients carrying a 
MLH1, MSH2, or MSH6 mutation. The recently published PREMM5 model is the only 
model that included PMS2 mutation carriers in its development. 
 
In this study we aimed to evaluate MMRpredict and PREMM5 in a clinical cohort and for 
PMS2 mutation carriers specifically. Additionally, we aimed to identify clinical features 
useful for distinguishing PMS2 mutation carriers from non-mutation carriers. 
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METHODS 
 
In a retrospective, clinic-based cohort we assessed the performance of MMRpredict and 
PREMM5 in predicting LS mutations in general and for MLH1, MSH2, MSH6 and PMS2 
mutations specifically. Additionally, we performed a univariate analysis to identify 
variables that can distinguish PMS2 mutation carriers from patients with no MMR 
mutation. 
 
Study population 
We collected data for all families that were referred for genetic counselling at Erasmus 
MC, Rotterdam, the Netherlands, and in which colorectal cancer was analyzed for MSI 
and/or IHC between 2000 and 2010. Exclusion criteria were: failed or inconclusive 
analysis for MSI and IHC, a pathogenic mutation in APC or MUTYH, a variant of unknown 
clinical significance in one of the MMR genes or APC, and MSI or IHC suspect for LS while 
no MMR mutation was detected. To increase the number of LS families, 35 LS families 
outside our cohort, diagnosed after 2010, were also included in the analysis. 
 
Analysis of MSI and IHC 
MSI analysis was carried out with five markers for MSI as described previously; up to 
2007 the Bethesda panel(28) was used and from 2007 onwards our center performs 
Promega pentaplex MSI analysis.(29) IHC for MLH1, MSH2, MSH6 and PMS2 protein was 
performed as described previously.(13) Tumours without MSI or only a low degree of 
MSI and with all MMR proteins present, were considered MMR proficient. Tumours 
showing a high degree of MSI and/or absence of one or more MMR proteins, were 
considered MMR deficient. MLH1 hypermethylation analysis was performed to 
distinguish between sporadic MMR deficient tumours and MMR deficient tumours 
suspect for LS. 
 
Germline mutation analysis 
Patients with MMR deficient tumours suspect for LS underwent germline mutation 
analysis of the gene indicated by IHC. Germline mutation analysis of MLH1, MSH2 and 
MSH6 was performed by sequencing and multiplex ligation dependent probe 
amplification analyses. PMS2 mutation analysis was performed as described 
elsewhere.(30) 
 
Family classification 
Tumour characteristics, age at diagnosis, results of molecular diagnostics and germline 
mutation analysis, and a detailed family history were collected from medical records. In 
every family the patient in whom MSI and/or IHC was analyzed, was labelled the index 
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patient. If more than one family member was screened for LS, the youngest CRC patient 
analyzed was considered the index patient. Index patients with MMR proficient tumours 
or sporadic MMR deficient tumours, were labelled non-mutation carriers. Families 
identified with a pathogenic MMR mutation were labelled LS families. 
 
Prediction Models 
For each index patient the probability of carrying a LS mutation according to MMRpredict 
and PREMM5 was calculated as previously described.(18, 20) For PREMM5, the equation 
was slightly different from the published equation, based on personal communications 
with F Kastrinos. See supplemental material (appendix 1) for the corrected PREMM5 
equation. 
 
Statistical analysis 
Data were analyzed using SPSS statistical software version 21.0. Differences between 
mutation carriers and non-mutation carriers were compared using the Chi-square test or 
Fishers’ exact test for frequencies, and by using the Mann Whitney U test for continuous 
data. These analysis were also performed to compare PMS2 mutation carriers with non-
mutation carriers. P-values <0.01 were considered statistically significant. 
 
Receiver operating characteristic curves were created for MMRpredict and PREMM5 by 
plotting the true positive rate (sensitivity) against the false positive rate (1- specificity). 
Performance of MMRpredict and PREMM5 was evaluated by the area under the receiver 
operating characteristic curve (AUC). We compared the AUC of PREMM5 and 
MMRpredict for LS patients in general and for the different MMR genes specifically. 
Sensitivity and specificity were calculated for cut-offs previously indicated by the 
developers of the models (5%, 10%, 20% and 40%). These values were compared with 
the sensitivity and specificity of the revised Bethesda guidelines. 
 
Model updating 
Location of CRC is included in MMRpredict, but not in the PREMM5 model. To update 
the PREMM5 model, we used a previously proposed framework to update multinomial 
logistic regression models.(31) We extended the PREMM5 model using recalibration and 
extension. The PREMM5 model contains four linear predictors, each contributing weights 
to the probability of carrying a mutation in MLH1, MSH2 (or EPCAM), MSH6 and PMS2. 
The coefficients of the linear predictors were constrained such that the linear predictor 
only contributed to the calculation of the corresponding mutation. Since the original 
PREMM5 model was developed on a population with no MSH6 mutation carriers with 
two or more CRCs, we developed two adaptations of the PREMM5 model. First we 
recalibrated the PREMM5 model and re-estimated the coefficient of the predictor ‘Two 
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or more CRCs’ in the linear predictor for MSH6. In the second adaptation we also added 
side of CRC as an additional predictor to the original PREMM5 model. Discriminative 
ability of the prediction models was quantified using the AUC. Calculations were done 
using R software (version 3.3.0), with estimation of the coefficients in the updated 
PREMM5 model using the VGAM package. 
 
Validation of the extended PREMM5 model 
For external validation of the extended PREMM5 model, we used a cohort of 376 CRC 
patients. Of these patients, 218 were patients with MMR proficient CRC, that where 
analyzed in the Erasmus Medical Center Rotterdam outside the dates of our initial 
cohort. LS patients (n=158) in our validation cohort were CRC patients from Leiden 
University Medical Center in whom an MMR mutation was found and with known 
location of CRC. For all patients of the validation cohort we calculated the probability of 
carrying an MMR mutation according to the original PREMM5 model and the extended 
model. The performance of both models were evaluated by comparing the AUC. 
 
 
RESULTS 
 
A total of 734 index patients were included in the study; 346 (47%) were male and mean 
age at time of diagnosis was 53 years (± 13 years). Overall, 569 (78%) patients fulfilled 
the revised Bethesda guidelines. Of the 734 index patients, 83 (11%) were diagnosed 
with a LS mutation; 23 MLH1, 17 MSH2, 31 MSH6 and 12 PMS2 mutation carriers. 
 
Patient characteristics 
Patient characteristics for mutation-positive and mutation-negative patients are shown 
in Table 1. Significantly more mutation carriers developed multiple CRCs (21% vs. 10%, 
p=0.005) and multiple LS-associated cancers in general (13% vs. 4%, p=0.002) than non-
mutation-carriers. CRC patients carrying an MMR mutation had a younger age of onset 
(49 years vs. 53 years, p=0.002) and more often had proximal CRCs (64% vs. 28%, 
p<0.001) than non-mutation carriers. Among women, the frequency of EC was higher for 
mutation carriers than for non-mutation carriers (41% vs. 3%, p<0.001). In the mutation 
positive group, first and second degree relatives developed CRC at a younger age than in 
the mutation negative group (50 vs. 64 years, p<0.001 and 47 vs 62 years, p=0.008). First 
degree relatives of mutation carriers had higher rates of EC than relatives of non-
mutation carriers (19% vs. 5%, p<0.001). 
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Discriminative ability of prediction models 
Overall, PREMM5 predicted higher probabilities of carrying a LS mutation than 
MMRpredict (median score 0.06 vs. 0.03, supplemental table 1). For mutation carriers, 
risk scores varied from 0.02 to 0.99 for PREMM5 and from 0.002 to 0.99 for MMRpredict. 
Both prediction models could fairly discriminate between index patients with and 
without an MMR mutation.(Figure 1) PREMM5 and MMRpredict had similar overall 
performance (AUC 0.72 [95% CI 0.66-0.79] vs. 0.73 [95% CI 0.66-0.79]). For MLH1 and 
MSH2 mutation carriers, both prediction models performed well, with AUC of 0.80 [95% 
CI 0.71-0.89] and 0.83 [95% CI 0.73-0.94] for PREMM5 and AUC of 0.79 [95% CI 0.69-0.89 
and 0.67-0.91] for MMRpredict. Both models had a fair discriminative power for MSH6 
mutation carriers (AUC of 0.69 [95% CI 0.58-0.80] for PREMM5 and AUC of 0.66 [95% CI 
Table 1. Index characteristics and family history by mutation status (n=734) 
 Mutation negative, % (n) Mutation positive, % (n) P value 
N 651 83  
Revised Bethesda guidelines 76% (494) 90% (75) 0.003 
    
Index characteristics    
Male gender 47% (305) 49% (41) 0.66 
Colorectal cancer    
    Age CRC (median, IQR) 53 years [45-62] 49 years [39-59] 0.002 
    Proximal CRC 28% (185) 64% (53) <0.001 
    ≥2 CRCs 10% (66) 21% (17) 0.005 
Endometrial cancer 3% (11) 41% (17) <0.001 
     Age EC (median, IQR) 55 years [50-75] 54 years [49-57] 0.18 
Multiple LS cancers 4% (27) 13% (11) 0.002 
    
First degree relatives    
Colorectal cancer 55% (358) 51% (42) 0.45 
     ≥2 FDRs with CRC 16% (107) 17% (14) 0.92 
     Age CRC (median, IQR) 64 years [55-71] 50 years [43-57] <0.001 
Endometrial cancer 5% (35) 19% (16) <0.001 
     ≥2 FDRs with EC 0.6% (4) 2% (2) 0.14 
     Age EC (median, IQR) 55 years [50-64] 50 years [45-57] 0.25 
Other LS cancers 22% (142) 19% (16) 0.60 
    
Second degree relatives    
Colorectal cancer 33% (212) 35% (29) 0.66 
     ≥2 SDRs with CRC 12% (81) 12% (10) 0.92 
     Age CRC (median, IQR) 62 years [50-74] 47 years [38-64] 0.008 
Endometrial cancer 3% (22) 7% (6) 0.12 
     ≥2 SDRs with EC 0.3% (2) 2% (2) 0.07 
     Age EC (median, IQR) 70 years [50-76] 49 years [44-51] 0.13 
Other LS cancers 16% (104) 18% (15) 0.63 
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0.56-0.76] for MMRpredict). MMRpredict still had fair performance for PMS2 mutation 
carriers (AUC of 0.72 [95% CI 0.57-0.87]), while PREMM5 failed to discriminate PMS2 
mutation carriers from non-mutation carriers at all with an AUC of 0.51 [95% CI 0.35-
0.66]. 
 
Figure 1. Performance of PREMM5 and MMRpredict in a clinical setting for all mutation carriers and for 
individual MMR mutations. 
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Sensitivity and specificity 
Using a cut-off of 5% for both prediction models, PREMM5 had a higher sensitivity than 
MMRpredict (78% vs. 70%). This higher sensitivity came at the expense of a lower 
specificity (46% vs. 67%). For MMRpredict, at a 5% cut-off sensitivity for MLH1 and MSH2 
mutation carriers were 74% and 77%, while sensitivity for PMS2 as well as MSH6 
mutation carriers were 65% and 67%. For both models, using a cut-off of ≥20% failed to 
identify over 50% of the mutation carriers. 
 
Sensitivity of the revised Bethesda guidelines decreased from 96% for MLH1 mutation 
carriers to 83% for PMS2 mutation carriers.(Supplemental table 2) Overall, the revised 
Bethesda guidelines had a sensitivity of 90% with a specificity of 24%. In order to reach 
the same sensitivity, PREMM5 and MMRpredict had a similar specificity (25%). 
 
PMS2 mutation carriers vs. non-mutation carriers 
Mutation carriers differed significantly from non-mutation carriers in many ways (Table 
1). In contrast, there were almost no significant differences between PMS2 mutation 
carriers and non-mutation carriers. Only one significant difference remained; PMS2 
mutation carriers more often had proximal CRC than patients without an MMR mutation 
(83% vs. 28%, p<0.001).(Table 2) 
 
Improvement of the PREMM5 model 
Since location of CRC was the only significant difference between PMS2 mutation 
carriers and non-mutation carriers, we incorporated this variable in the PREMM5 model, 
aiming to improve the prediction model. For PMS2 mutation carriers, the extended 
PREMM5 model had considerably better predictions than the original PREMM5 model 
(AUC 0.77 [95% CI 0.63-0.90] vs. 0.51 [95% CI 0.35-0.66])(Figure 2). At a 5% cut-off, the 
new PREMM5 model identified 5/6 PMS2 mutation carriers that would have been missed 
by PREMM5 and 3/4 PMS2 mutation carriers that would have been missed by 
MMRpredict at the same cut-off. 
 
Adding tumour location also improved the performance of PREMM5 for identifying 
MLH1 (AUC 0.92 [95% CI 0.88-0.97] vs. 0.80 [95% CI 0.71-0.89]) and MSH6 (AUC 0.75 
[95% CI 0.65-0.84] vs. 0.69 [95% CI 0.58-0.80]) mutation carriers (Figure 2). However, 
performance for MSH2 mutation carriers slightly decreased (AUC 0.80 [95% CI 0.69-0.91] 
vs. 0.83 [95% CI 0.73-0.94]). Overall, the adjusted PREMM5 model performed better than 
the original PREMM5 model (AUC 0.81 [95% CI 0.76-0.86] vs. 0.72 [95% CI 0.66-0.79]) 
and MMRpredict (AUC 0.81 vs 0.73 [95% CI 0.66-0.79]). The adjusted prediction model 
can be found as supplemental material. 
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At a 5% cut-off, sensitivity of the extended PREMM5 model was higher than the 
sensitivity of the original PREMM5 model (92% vs 78%) with similar specificity (45% vs. 
46%). Sensitivity and specificity of the extended PREMM5 model at a 5% cut off were 
both higher than those of the revised Bethesda guidelines (sensitivity 92% vs. 90% and 
specificity 45% vs. 24%) 
 
Validation of the extended PREMM5 model 
In our validation cohort, 60% of the patients were male and median age was 55 years 
(IQR 45-63 years). The cohort included 31 MLH1, 26 MSH2, 28 MSH6 and 73 PMS2 
mutation carriers. Similar to the results in the initial cohort, the extended PREMM5 
Table 2. Index characteristics and family history for PMS2 mutation carriers compared with non-mutation 
carriers 
 Mutation negative, % (n) PMS2 mutation positive, % (n) P value 
N 651 12  
Revised Bethesda guidelines 76% (494) 83% (10) 0.74 
    
Index characteristics    
Male gender 47% (305) 50% (6) 0.83 
Colorectal cancer    
    Age CRC (median, IQR) 53 years [45-62] 46 years [40-61] 0.21 
    Proximal CRC 28% (185) 83% (10) <0.001 
    ≥2 CRCs 10% (66) 8% (1) 1.0 
Endometrial cancer 3% (11) 0% (0) 1.0 
     Age EC (median, IQR) 55 years [50-75]   
Multiple LS cancers 4% (27) 0% (0) 1.0 
    
First degree relatives    
Colorectal cancer 55% (358) 42% (5) 0.36 
     ≥2 FDRs with CRC 16% (107) 8% (1) 0.70 
     Age CRC (median, IQR) 64 years [55-71] 62 years [45-90] 0.68 
Endometrial cancer 5% (35) 17% (2) 0.14 
     ≥2 FDRs with EC 0.6% (4) 8% (1) 0.88 
     Age EC (median, IQR) 55 years [50-64] 37 years [ - ] 0.24 
Other LS cancers 22% (142) 8% (1) 0.48 
    
Second degree relatives    
Colorectal cancer 33% (212) 17% (2) 0.35 
     ≥2 SDRs with CRC 12% (81) 8% (1) 1.0 
     Age CRC (median, IQR) 62 years [50-74] 39 years [39- ] 0.12 
Endometrial cancer 3% (22) 8% (1) 0.35 
     ≥2 SDRs with EC 0.3% (2) 8% (1) 0.05 
     Age EC (median, IQR) 70 years [50-76] 49 years [ - ] 0.67 
Other LS cancers 16% (104) 17% (2) 1.0 
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model had better predictions than the original PREMM5 model for PMS2 mutation 
carriers (AUC 0.90 [95% CI 0.86-0.94] vs. 0.82 [95% CI 0.76-0.87]) and overall (AUC 0.92 
[95% CI 0.89-0.95] vs. 0.87 [95% CI 0.84-0.91] ). Performance for MLH1, MSH2 and MSH6 
mutation carriers was also slightly better for the extended PREMM5 model than for the 
original PREMM5 model (AUC 0.97 [95% CI 0.94-1.00] vs. 0.95 [95% CI 0.91-0.99] for 
MLH1, 0.97 [95% CI 0.93-1.00] vs. 0.96 [95% CI 0.92-0.99] for MSH2 and 0.86 [95% CI 
0.97-0.93] vs. 0.85 [95% CI 0.77-0.93] for MSH6 mutation carriers). 
 
Figure 2. Performance of PREMM5 and the extended PREMM5 model in a clinical setting for all mutation 
carriers and for individual MMR mutations. 
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DISCUSSION 
 
The results of our study indicate that while the models MMRpredict and PREMM5 can 
adequately predict whether an individual is likely to have Lynch syndrome, they fail to 
identify PMS2 mutation carriers. The performance of the PREMM5 model improved 
considerably by adding the location of CRC to the model. In our clinical cohort of 734 CRC 
patients as well as in a validation cohort of 376 CRC patients, this extended PREMM5 
model not only identified PMS2 mutation carriers more accurately, its overall 
performance was also better than the original PREMM5 model and the MMRpredict 
model. 
 
Our results are in line with those of previous studies, where the PREMM1,2,6 model had a 
slightly better overall performance than MMRpredict.(22, 32, 33) The first PREMM 
model, PREMM1,2 also performed better than MMRpredict in several studies(23, 24), but 
had similar(25, 26) or less accurate(21) predictions in other studies. A recent meta-
analysis also found pooled AUCs to be higher for the PREMM model than for 
MMRpredict (AUC 0.84 vs. 0.81).(27) 
 
Although PREMM5 had better overall predictions, MMRpredict had a better 
performance for PMS2 mutation carriers specifically. An explanation for this could be 
that the location of CRC is incorporated in the MMRpredict model but not in the 
PREMM5 model. Proximal location of CRC is a known predictor for Lynch syndrome and 
in our cohort was the only significant difference between PMS2 mutation carriers and 
non-mutation carriers. After adding this new variable to the existing PREMM55 model, 
this new model performed better than MMRpredict for PMS2 mutation carriers. The 
extended PREMM55 model also performed better than the original model for MLH1, 
MSH2 and MSH6 mutation carriers and had a better overall performance. 
 
In our validation cohort, all AUCs were much higher than in our original cohort, including 
those for PMS2 mutation carriers. Selection of patients for analysis of MSI and IHC may 
have been less stringent at the Erasmus Medical Center Rotterdam than at the Leiden 
University Medical Center. Therefore, mutation carriers in our validation cohort, who 
were all from Leiden University Medical Center, may have had a family history more 
suspect for Lynch syndrome than family history of the patients in our original cohort. 
This could explain the higher AUCs in the validation cohort. However, in both cohorts we 
showed that the extended PREMM5 had better performance. 
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Prediction models for Lynch syndrome are not yet regularly used in current clinical 
practice. However, the US Multi-Society Task Force on Colorectal Cancer recommends 
genetic evaluation if an individual’s risk of carrying an MMR gene mutation is ≥5% 
according to one of the prediction models MMRpro, MMRpredict or PREMM.(34) The 
American guideline recommends that all CRC patients undergo routine screening for LS 
by analysis of MSI and IHC(34), while current European guidelines recommend such 
routine screening in at least all CRC patients up to 70 years of age.(35) A recent study 
demonstrated that routine screening for LS without an age cut-off is not cost-
effective.(36) A strategy using prediction models might lower the cost of screening for 
LS. In fact, two cost-effectiveness analyses found that strategies including prediction 
models were more cost-effective than those involving direct tumour testing of all CRC 
patients, if these prediction models were perfectly implemented.(36, 37) Additionally, 
prediction models could also be used in cases where no tumour tissue is available or 
where tumour tissue analysis failed, to assess whether an individual should be analyzed 
for a germline MMR mutation. 
 
The US Multi-Society Task Force on Colorectal Cancer recommends the use of either 
PREMM, MMRpredict or MMRpro to assess the probability of an individual carrying an 
MMR mutation.(34) Since we did not include the MMRpro model in our analysis, we do 
not know how MMRpro would have performed in our cohort. However, MMRpro is less 
useful in clinical practice since extensive family data is needed as input for the model. 
Collection of this kind of data is very time consuming and therefore not suitable for 
clinical practice. PREMM5 and MMRpredict are web-based models that are easily 
accessible and therefore much easier to use. Also, multiple studies - including the recent 
meta-analysis – have shown MMRpro to have similar accuracy to PREMM1,2,6.(21-27, 32) 
 
Both PREMM5 and MMRpredict were far more accurate for MLH1 and MSH2 mutation 
carriers than for LS patients carrying a mutation in MSH6 or PMS2. This finding is in line 
with a previous study that showed that carriers of mutations in MSH6 or PMS2 had lower 
risk scores than carriers of a mutation in MLH1 or MSH2.(21) In our study, discrimination 
between non-mutation carriers and PMS2 mutation carriers was the least accurate, in 
line with its more limited penetrance. 
 
Around 15% of all Lynch syndrome cases are estimated to be caused by PMS2 
mutations.(38) In our cohort, 14% (12/83) of the Lynch syndrome patients were PMS2 
mutation carriers. To our knowledge, our study is the first to validate LS prediction 
models for PMS2 mutation carriers specifically since the development of the PREMM5 
model. At a 5% cut-off, our extended PREMM5 model was able to detect five out of six 
PMS2 mutation carriers who would have been missed by the original PREMM5 model at 
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the same cut-off. Identification of Lynch syndrome carriers is highly important, since this 
allows not only them, but also their family members carrying the same mutation, to 
undergo intensive surveillance in order to prevent the development of cancer. Our new 
model would also identify more Lynch syndrome patients overall than the original 
PREMM5 model. 
 
The performance of prediction models can differ between high-risk settings and 
population-based cohorts. Further validation studies should indicate whether our results 
can be generalized to settings with patients at low to median risk of having Lynch 
syndrome. Since patients in our study cohort were all referred for genetic counselling, 
family histories were obtained in detail and in many cases also verified by medical 
documents. In other settings where patients are at lower risk of having Lynch syndrome, 
family history is not verified and might be less reliable. Therefore, prediction models 
should also be validated in population-based cohorts. However, in a meta-analysis, 
prediction models performed better in population-based cohorts than in clinic-based 
cohorts.(27) 
 
It is not known whether the current prediction models for Lynch syndrome are useful in 
non-Western populations. In a recent study among Korean patients, PREMM1,2,6 was 
more accurate than MMRpro and MMRpredict, but still only reached an AUC of 0.71.(32) 
There was no association between tumour location and mutation status, so our 
extended PREMM5 model might not improve predictions in populations of non-Western 
ethnicity. However, germline analysis for PMS2 was not performed in the Korean study, 
so there might have been more mutation carriers in their cohort. Another non-Western 
population has been studied by Khan et al, who analyzed the performance of prediction 
models in 15 African American patients.(22) In these patients, MMRpredict and 
PREMM1,2,6 both had a high AUC of 0.89. 
 
A main strength of our study was the large cohort, which consisted of more than 700 
index patient including 83 Lynch syndrome patients. Also, our cohort included patients 
with MSH6 and PMS2 mutations. Since 12 patients were identified as a PMS2 mutation 
carrier, we were able to evaluate the prediction models for each MMR mutation 
specifically, admittedly with considerable uncertainty.(39) Furthermore, we validated the 
extended PREMM5 model in a separate cohort of 376 patients including 73 PMS2 
mutation carriers. 
  
A limitation of our study was that germline mutation analysis was not done for all index 
patients. Patients who had microsatellite stable tumours with normal IHC were assumed 
to be non-mutation carriers. However, some of these patients might still have an MMR 
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mutation. Also, the sample size per gene was still relatively small and it is unclear 
whether our results from a high-risk population apply to a population-based setting. 
 
In conclusion, we have shown that although MMRpredict and PREMM5 can accurately 
predict an individual’s risk of carrying a causative MMR mutation, neither model is able 
to identify patients with PMS2 mutations. Adding the location of CRC to the PREMM5 
model improves the performance of the model for PMS2 mutation carriers as well as its 
overall performance. These findings should be validated in large cohorts from 
population-based settings. 
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SUPPLEMENTAL MATERIAL 
 
Equation PREMM5 model 
Predicted probability of any mismatch repair gene mutation: p(any)= predicted probability of 
MLH1 mutation + predicted probability of MSH2/EPCAM mutation + predicted probability of MSH6 
mutation+ predicted probability of PMS2 mutation. 
 
Predicted probability of a mutation in MLH1: p(MLH1) 
Predicted probability of a mutation in MSH2 or EPCAM: p(MSH2/EPCAM) 
Predicted probability of a mutation in MSH6: p(MSH6) 
Predicted probability of a mutation in PMS2: p(PMS2) 
Predicted probability of no mutation: p(none) = 1- [p(MLH1) + p(MSH2) + p(MSH6) + p(PMS2)] 
 
p(MLH1)= exp (lp(MLH1)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + exp(lp(MLH6)) + 
exp(lp(PMS2)))] 
p(MSH2/EPCAM)= exp (lp(MSH2/EPCAM)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + 
exp(lp(MLH6)) + exp(lp(PMS2)))] 
p(MSH6)= exp (lp(MSH6)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + exp(lp(MLH6)) + 
exp(lp(PMS2)))] 
p(PMS2= exp (lp(PMS2)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + exp(lp(MLH6)) + 
exp(lp(PMS2)))] 
 
lp(MLH1) = -5.402 + (0.901*V0) + (2.586*V1) + (3.171*V2) + (1.620*V3) + (1.275*V4) + (1.578*V5) 
+ (0.804*V6) + (0.391*V7) + (-0.594*(V8/10)) + (0.122*(V9/10)) + (-0.458*(V10/10)). 
 
lp(MSH2/EPCAM) = -4.480 + (0.933*V0) + (1.799*V1) + (2.586*V2) + (1.922*V3) + (1.582*V4) + 
(1.353*V5) + (0.670*V6) + (0.605*V7) + (-0.468*(V8/10)) + (0.004*(V9/10)) + (-0.470*(V10/10)). 
 
lp(MSH6) = -4.672 + (0.815*V0) + (1.266*V1) + (-53.181*V2) + (1.755*V3) + (0.536*V4) + 
(0.549*V5) + (0.916*V6) + (0.315*V7) + (-0.099*(V8/10)) + (0.352*(V9/10)) + (-0.363*(V10/10)). 
 
lp(PMS2) = -4.922 + (0.293*V0) + (0.990*V1) + (-0.353*V2) + (0.739*V3) + (0.394*V4) + (0.003*V5) 
+  
(-0.425*V6) + (-0.105*V7) + (-0.089*(V8/10)) + (0.006*(V9/10)) + (-0.071*(V10/10)). 
 
Equation based on published equation and personal communications with F Kastrinos. 
All variables are equal to the original PREMM5 model: Kastrinos et al, JCO 2017. 
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Equation extended PREMM5 model 
 
Predicted probability of any mismatch repair gene mutation: p(any)= predicted probability of 
MLH1 mutation + predicted probability of MSH2/EPCAM mutation + predicted probability of MSH6 
mutation+ predicted probability of PMS2 mutation. 
 
Predicted probability of a mutation in MLH1: p(MLH1) 
Predicted probability of a mutation in MSH2 or EPCAM: p(MSH2/EPCAM) 
Predicted probability of a mutation in MSH6: p(MSH6) 
Predicted probability of a mutation in PMS2: p(PMS2) 
Predicted probability of no mutation: p(none) = 1- [p(MLH1) + p(MSH2) + p(MSH6) + p(PMS2)] 
 
p(MLH1)= exp (lp(MLH1)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + exp(lp(MLH6)) + 
exp(lp(PMS2)))] 
p(MSH2/EPCAM)= exp (lp(MSH2/EPCAM)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + 
exp(lp(MLH6)) + exp(lp(PMS2)))] 
p(MSH6)= exp (lp(MSH6)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + exp(lp(MLH6)) + 
exp(lp(PMS2)))] 
p(PMS2= exp (lp(PMS2)) / [(1 + exp((lp(MLH1)) + exp(lp(MSH2/EPCAM)) + exp(lp(MLH6)) + 
exp(lp(PMS2)))] 
 
lp(MLH1) = -7.010 + (0.677*V0) + (1.942*V1) + (2.381*V2) + (1.216*V3) + (0.957*V4) + (1.185*V5) 
+ (0.604*V6) +(0.294*V7) + (-0.446*(V8/10)) + (0.092*(V9/10)) + (-0.344*(V10/10)) + (3.280*V11). 
 
lp(MSH2/EPCAM) = -5.269 + (0.868*V0) + (1.674*V1) + (2.407*V2) + (1.789*V3) + (1.472*V4) + 
(1.259*V5) + (0.624*V6) + (0.563*V7) + (-0.436*(V8/10)) + (0.004*(V9/10)) + (-0.437*(V10/10)) + 
(0.728*V11). 
 
lp(MSH6) = -4.005 + (0.796*V0) + (1.237*V1) + (1.520*V2) + (1.714*V3) + (0.524*V4) + (0.536*V5) 
+ (0.895*V6) + (0.308*V7) + (-0.097*(V8/10)) + (0.344*(V9/10)) + (-0.355*(V10/10)) + (0.868*V11). 
 
lp(PMS2) = -5.511 + (0.040*V0) + (0.134*V1) + (-0.048*V2) + (0.100*V3) + (0.053*V4) + (0.000*V5) 
+ (-0.058*V6) + (-0.014*V7) + (-0.012*(V8/10)) + (0.001*(V9/10)) + (-0.010*(V10/10)) + 
(2.540*V11). 
 
 
V11: Side of colorectal cancer. Enter 0 for left-sided, enter 1 for right-sided. 
All other variables are equal to the original PREMM5 model. 
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ABSTRACT 
 
Purpose To assess the cost-effectiveness of routine Lynch syndrome (LS) screening 
among colorectal cancer (CRC) patients ≤70 years of age. 
Methods A population-based series of CRC patients ≤70 years was routinely screened for 
LS. We calculated life years gained (LYG) and incremental cost-effectiveness ratios 
(ICERs) for different age cut-offs and comparing age-targeted screening with the revised 
Bethesda guidelines. 
Results Screening 1117 CRC patients identified 23 LS patients, of whom 7 were ≤50, 7 
were 51-60 and 9 were 61-70 years. Additionally, 70 LS carriers were identified among 
relatives (14, 42 and 14 per age category). Screening amounted to 205.9 LYG or 43.6, 
118.0 and 44.3 LYG per age category. ICERs were €4.226/LYG for screening CRC patients 
≤60 years compared with ≤50 years and €7.051/LYG for screening CRC patients ≤70 years 
compared with ≤60 years. The revised Bethesda guidelines identified 70/93 (75%) LS 
carriers. The ICER for LS screening in CRC patients ≤70 years compared with the revised 
Bethesda guidelineswas €7.341/LYG. All ICERs remained <€13.000/LYG in one-way 
sensitivity analyses. 
Conclusion Routine LS screening by analysis of microsatellite instability, immuno-
histochemistry and MLH1 hypermethylation in CRC patients ≤70 years is a cost-effective 
strategy with important clinical benefits for CRC patients and their relatives. 
  
Cost-effectiveness of Lynch syndrome screening in colorectal cancer patients 
49 
4 
INTRODUCTION 
 
Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, 
responsible for 2-3% of all CRC cases.(1-3) This syndrome is characterized by early onset 
of CRC, endometrial cancer and other extracolonic cancers.(4) Mutations in one of the 
four mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 or the EPCAM gene 
are the underlying defect in LS.(5) Detection of LS in CRC patients is of great importance, 
since affected patients and family members can benefit from LS surveillance programs, 
which reduce CRC incidence and mortality by 56-70%.(6, 7) 
 
Molecular diagnostics on tumour tissue consisting of analysis for microsatellite instability 
(MSI) and immunohistochemical staining (IHC) for loss of MMR protein expression can 
identify patients at high risk of having LS.(8, 9) However, loss of MLH1 protein expression 
can also occur in sporadic tumours as a result of somatic MLH1 promoter 
hypermethylation. Therefore, sporadic MLH1 deficient tumours can be distinguished 
from LS-associated tumours by MLH1 hypermethylation analysis.(9) 
 
The revised Bethesda guidelines have been developed to select patients eligible for MSI 
testing and IHC analysis based on clinical criteria.(10) These guidelines are poorly applied 
in clinical practice and may miss a substantial number of LS patients because of limited 
sensitivity.(11) Routine analysis of MSI and IHC was previously recommended in CRC 
patients under 50 years of age.(12) This strategy predominantly fails to identify MSH6 
and PMS2 mutation carriers, since the mean age of CRC diagnosis in these subjects is 
above the age of 50 years.(13, 14) Routine screening for LS has been proposed to 
improve LS detection, but age cut-offs are still under debate.(15-17) Recently, the US 
Multi-Society Task Force on Colorectal Cancer as well as a European group of experts 
recommended routine LS screening by analysis of MSI or IHC and MLH1 
hypermethylation in CRC patients.(18, 19) The US guidelines support universal tumor 
testing for LS, while the European guidelines recommend routine LS screening in all CRC 
patients or in CRC patients up to 70 years of age.  
 
We previously reported that routine analysis of MSI and IHC for MMR proteins revealed 
a profile compatible with LS in 4.5% of CRC patients ≤70 years of age.(20) Many of these 
patients were over 50 years of age.(20) The current study aimed to assess the cost-
effectiveness of routine screening for LS by analysis of MSI, IHC and MLH1 
hypermethylation in CRC patients ≤70 years of age. We compared costs and health 
benefits for age-targeted LS screening up to 70 years of age. Also, we compared routine 
LS screening among CRC patients up to age 70 with LS screening based on the revised 
Bethesda guidelines. 
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METHODS 
 
Subjects and diagnostic work-up 
The present study is an extension of a prospective population-based study on the yield of 
routine molecular screening for LS in CRC patients up to 70 years of age.(20) Consecutive 
CRC patients ≤70 years of age (n=1117) from 11 Dutch hospitals were included between 
May 2007 and September 2009. The diagnostic approach and methods regarding tumour 
analyses and germline mutation analyses have been described in detail elsewhere.(20) In 
summary, MSI analysis and IHC for MLH1, MSH2, MSH6 and PMS2 protein expression 
were performed in tumour tissue of CRC patients ≤70 years of age. MLH1 
hypermethylation analysis was performed in cases with loss of MLH1 protein expression. 
BRAF mutation analysis was not included in this cost study, since previous studies have 
shown that MLH1 promoter hypermethylation analysis is a superior prescreening 
method compared to BRAF mutation analysis.(21) In case tumours showed a high degree 
of MSI and/or absence of MMR protein without MLH1 promoter hypermethylation, 
patients were suspected of having LS. These patients were offered genetic counselling 
and germline mutation analysis (Figure 1). In case patients suspected of having LS had 
deceased before they could be referred to a clinical geneticist, genetic counselling was 
offered to their first degree relatives. In the Netherlands, costs for genetic counselling 
and germline mutation analysis are covered by the mandatory basic health insurance. 
 
If a pathogenic germline mutation was identified in one of the MMR genes or the EPCAM 
gene, patients were labelled index patients. Relatives were contacted by index patients 
and were offered genetic counselling and targeted mutation analysis. We collected data 
on the number of relatives accepting counselling and targeted mutation analysis and the 
number of LS carriers identified among these relatives until May 2014. This study was 
approved by the Institutional Review Boards of the participating hospitals. 
 
Effectiveness 
Effectiveness of LS screening was expressed in life years gained (LYG), based on the 
number of LS carriers detected among CRC patients and their relatives and using 
estimations from literature. In previous studies LS surveillance was associated with 0.09-
2.5 LYG for index patients and 0.49-32.69 LYG for relatives.(12, 16, 17, 22-29) For our 
analysis, we directly used the reported 3% discounted LYG from previous studies. If only 
undiscounted LYG or LYG with a different discount rate were reported, we discounted 
them by 3% annually (Supplementary information, Table S1). If adherence to LS 
surveillance programs was not included in the reported LYG, we corrected the LYG by 
assuming adherence to these programs of 80% for both index patients and LS carriers 
among their relatives.(16) We used the median of all estimations from the literature in 
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our base case scenario (Table 1). If the index patient had deceased, only relatives were 
considered to benefit from surveillance. For CRC patients and relatives without a 
pathogenic mutation identified, we assumed no surveillance costs or benefits.  
 
Costs 
Direct medical costs of all analyses in the diagnostic work-up were determined following 
the microcosting method, which is based on comprehensive bottom-up analyses.(30) 
Cost data included costs of employment, material, equipment and overhead, which were 
obtained from the Department of Pathology and the Department of Clinical Genetics of 
the Erasmus MC, University Medical Center Rotterdam (Supplementary information, 
Table S2). Costs for PMS2 germline mutation analysis were assumed to be similar to cost 
for germline mutation analysis of other MMR genes. Total costs were calculated based 
on the number of CRC patients and relatives analyzed. The costs for MMR gene 
sequencing in index patients were calculated using the total number of genes analyzed. 
LS surveillance costs for index patients and relatives were estimated from previous 
literature including costs for colonoscopy, transvaginal ultrasonography and endometrial 
biopsy (Table 1 and Table S2).(16, 31) Costs for gynaecological screening were only 
available in dollars and were converted to euros using purchasing power parity. All costs 
were converted to price level 2013 using the Dutch consumer price index.(32) 
Surveillance by colonoscopy with polypectomy every two years was assumed to start at 
the age of LS diagnosis or at age 25 for relatives under 25 years of age. LS surveillance 
was assumed to be continued until 75 years of age. For cost savings by prevention of CRC 
in surveillance programs, the most conservative estimate i.e. only treatment costs for 
the first 12 months of stage I CRC was used (Table S2). Female LS carriers were assumed 
to receive yearly gynaecological surveillance by transvaginal ultrasonography and 
endometrial biopsy starting at age 35 and continued until prophylactic surgery at 40 
years of age, after childbearing is completed. Prophylactic surgery (total abdominal 
hysterectomy and bilateral salpo-oophorectomy) was assumed to be accepted by 19% of 
the index patients and 18% of their relatives.(16) LS carriers not accepting prophylactic 
surgery were assumed to continue yearly gynaecological surveillance up to 75 years of 
age. All costs were discounted by 3% annually. 
 
Cost-effectiveness analyses 
We evaluated cost-effectiveness of LS screening using a base-case cost-effectiveness 
model (i.e. using the most plausible parameter values), and age cut-offs of 60, and 70 
years from a health care provider perspective. LS screening for CRC patients ≤50 years 
was the reference strategy. Incremental cost-effectiveness ratios (ICERs) per age cut-off 
were expressed as additional costs per LYG. In order to test the robustness of ICERs we 
performed one-way sensitivity analyses. Costs were assumed to range from 0.5 to 2 
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times as much as calculated. Ranges for all other parameters were based on literature 
(Table 1).  
 
Fulfilment of the revised Bethesda guidelines 
The proportion of CRC patients fulfilling the revised Bethesda guidelines was based on 
the literature (Table 1). In an unselected population, 26-50% of CRC patients fulfil the 
revised Bethesda guidelines.(1, 3, 33) We assumed only 26% of the CRC patients in our 
cohort fulfilled these guidelines, since this approach is unfavourable for an age-targeted 
screening strategy. For all index patients, a detailed family history was obtained during 
genetic counselling and fulfilment of the revised Bethesda guidelines was assessed by 
one clinical geneticist (AW). 
 
LS: Lynch syndrome; CRC: Colorectal cancer. 
† Life years gained were discounted by 3% annually 
 
 
RESULTS 
 
In our population-based cohort 50 out of 1117 CRC patients (4.5%) were suspected of 
having LS by routine analysis of MSI and IHC (Figure 1). Consecutive MMR gene 
sequencing in 42 of these CRC patients finally identified 24 LS patients (2.1%). In one 
case the germline mutation was identified in stromal tissue resected along with the CRC 
Table 1. Parameters and values used in the cost-effectiveness analysis 
Parameter Base case Range Source 
Median age at LS diagnosis    
Index patients 57 IQR 49-63 (20) 
Relatives 41 IQR 32-56 Current study 
 Female index patients 61 IQR 53-66 Current study 
 Female relatives 38 IQR 29-56 Current study 
    
LS surveillance    
Discounted life years gained†    
 Female index patients 0.66 0.191-2.15 (12, 16, 23, 24, 26, 27) 
 Male index patients  0.66 0.092-2.15 (12, 16, 23, 24, 26, 27) 
 Female relatives  2.83 0.40-16.02 (12, 16, 17, 22-29) 
 Male relatives 2.83 0.47-16.47 (12, 16, 17, 22-29) 
Interval between colonoscopies (years) 2 1-2 (18, 19) 
Complication rate of colonoscopy 0.0024  (31) 
Acceptance of prophylactic gynaecological surgery    
 Index patients 0.19 0.10-0.30 (16) 
 Relatives 0.18 0.03-0.25 (16) 
    
CRC risk and risk reduction    
Lifetime risk of developing CRC for LS carriers 0.25 0.25-0.70 (6, 7, 28, 34) 
Reduction in CRC risk by LS surveillance 0.56 0.56-0.70 (6, 7) 
    
Revised Bethesda guidelines    
Proportion of CRC patients fulfilling the revised  
Bethesda guidelines in an unselected CRC population 
 
0.26 
 
0.26-0.50 
 
(1, 35) 
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tissue. Since this patient nor any relatives were available for MMR gene sequencing, this 
patient was not considered an index patient. 
 
Figure 1. Diagnostic work-up to detect Lynch syndrome among colorectal cancer patients ≤70 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSI: microsatellite instability; MSS: microsatellite stable; MMR: mismatch repair; MSI-High, high degree of MSI; 
CRC; colorectal cancer; VUS: variant of unknown significance. 
† In 4/41 cases germline mutation analysis was performed in a first-degree relative. 
‡ In one patient a pathogenic MMR mutation was identified in stromal tissue resected during colorectal cancer 
surgery. This patient nor any family members were available for germline mutation analysis and this patients 
was excluded from the analyses. 
 
 
Effectiveness of age-targeted strategies 
The median age of CRC patients was 61 years (IQR 55-66); 144 CRC patients were ≤50 
years, 377 CRC patients 51-60 years and 596 CRC patients 61-70 years of age. The 
prevalence of LS decreased from 4.9% (7/144) in the age category ≤50 years to 2.1% 
(8/377) in CRC patients 51-60 years of age and 1.5% (9/596) in CRC patients 61-70 years 
of age (Table 2). 
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For index patients ≤50 years of age a total of 29 first degree relatives were eligible for 
targeted mutation analysis, compared with 44 and 40 first degree relatives in the age 
categories 51-60 years and 61-70 years respectively. Genetic counselling and targeted 
mutation analysis was offered to these relatives and cascaded to further relatives if 
indicated. For each index patient a median of 3 (IQR 2-8) relatives finally accepted 
counselling and germline targeted mutation analysis. There was a wide range from 1-37 
relatives tested for LS. In total, targeted mutation analysis was accepted by 140 relatives, 
identifying 70 additional LS carriers. Notably, over three times as many LS carriers were 
identified among relatives of CRC patients 51-60 years of age as in the other age 
categories (Table 2). This difference was partly attributable to one index patient in the 
51-60 age category with 37 relatives tested and 16 LS carriers identified. 
 
Based on a median estimated benefit of LS surveillance of 0.66 years per index patient 
and 2.83 years per relative, a total of 205.9 life years were estimated to be gained by LS 
screening in CRC patients ≤70 years of age. Surveillance of relatives led to the highest 
benefit with a total of 192.7 LYG compared with a total of 13.2 LYG for index patients. 
 
 
Table 2. Number of patients screened and detection of Lynch syndrome among CRC patients and relatives 
 
Colorectal cancer patients (n=1117) 
 
<50 
years 
 
51-60 years 
 
61-70 years 
Revised 
Bethesda 
guidelines 
 
Total 
LS diagnostics in CRC patients      
 Analysis for MSI and IHC 144 377 596 290 1117 
 MLH1 hypermethylation analysis 6 21 65 6 92 
 CRC patients suspected of having LS 15 15 20 27 50 
 Genetic counseling 12 13 17 25 42 
 Germline mutation analysis 11 13 17 23 41 
 Genes tested in CRC patients or FDR 18 22 30 30 70 
  LS index patients identified 7 7† 9 17 23† 
  Female LS index patients identified 1 3 5 8 9 
      
LS diagnostics in relatives      
Relatives accepting genetic counseling 25 78 38 99 141 
Germline mutation analysis 25 77 38 98 140 
  LS carriers identified among relatives 14 42 14 53 70 
  Female LS carriers identified among relatives 11 23 6 32 40 
      
Life years gained      
LYG by male index patients 3.3 2.6 1.3 0.6 7.3 
LYG female index patients 0.7 2.0 3.3 1.5 5.9 
LYG by male relatives 8.5 51.0 22.7 10.1 82.2 
LYG by female relatives 31.2 62.3 17.0 15.0 110.5 
Total LYG (index and relatives) 43.6 118.0 44.3 27.3 205.9 
Numbers of life years gained may not add up due to rounding. 
LS: Lynch syndrome; CRC: Colorectal cancer; MSI: Microsatellite instability; IHC: Immunohistochemistry;  
FDR: First degree relative; LYG: Life years gained. 
† In one additional case a germline mutation was identified in stromal tissue resected along with the CRC tissue. This patient 
was not considered an index patient, since the patient nor any relatives were available for germline mutation analysis. 
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Costs and cost-effectiveness 
Total costs for LS molecular screening and subsequent surveillance increased from 
€229.166 (€10.931 per LS carrier detected) for CRC patients ≤50 years of age to 
€1.040.005 (€11.183 per LS carrier detected) for CRC patients ≤70 years of age (Figure 2). 
 
 
Figure 2. Total costs and life years gained (LYG) for Lynch syndrome screening in colorectal cancer patients ≤50 
years of age, ≤60 years of age and ≤70 years of age. ICERs (Incremental cost-effectiveness ratios) are expressed 
as incremental cost per additional LYG compared with the previous strategy.  
 
 
LS screening for CRC patients ≤60 years of age had an ICER of €4.226/LYG compared with 
screening patients ≤50 years of age. The ICER of LS screening in CRC patients ≤70 years of 
age compared with screening CRC patients ≤60 years of age was €7.051 per LYG (Table 
3). 
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Table 3. Incremental costs in 2013 euro for Lynch syndrome screening in CRC patients of different age 
categories 
Colorectal cancer patients (n=1117) <50 years 51-60 years 61-70 years Total 
Lynch syndrome diagnostics     
CRC patients     
 Molecular diagnostics € 32.914  € 86.697  € 140.220  € 259.831  
 Genetic counseling € 3.574  € 3.872  € 5.064  € 12.510  
 MMR gene sequencing € 9.680  € 11.832  € 16.134  € 37.646  
Relatives     
 Genetic counseling € 4.003  € 13.009  € 6 .171  € 23.183  
 Targeted mutation analysis € 7.297  € 23.410  € 11.249  € 41.955  
     
Lynch syndrome surveillance     
Colonoscopy surveillance     
 Index patients € 27.929  € 19.924  € 12.358  € 60.211  
 Relatives € 61.226  € 174.933  € 61.226  € 297.385  
Gynaecologic surveillance and prophylactic surgery     
 Index patients € 5.754  € 24.263  € 25.634  € 55.651  
 Relatives € 91.970  € 183.939  € 49.465  € 325.374  
Savings by prevention of CRC - € 15.182  - € 43.378  - € 15.182   - € 73.743  
     
Total costs (minus savings) € 229.166  € 498.501  € 312.338  € 1.040.005  
Total life years gained 43.6 118.0 44.3 205.9 
Costs per life year gained reference € 4.226 € 7.051 - 
 
 
DISCUSSION 
 
Our economic evaluation indicates that routine screening for LS in CRC patients ≤70 
years of age by analysis of MSI, IHC and MLH1 hypermethylation is cost-effective 
according to currently accepted standards. In a one-way sensitiviy analysis, expanding 
routine screening for LS from CRC patients ≤50 years of age to CRC patients ≤60 years of 
age never exceeded €10.000/LYG. Costs for LS screening among CRC patients 61-70 years 
of age were €7.051/LYG in our base case analysis and remained <€13.000/LYG in one-
way sensitivity analysis. The cost-effectiveness threshold of any diagnostic strategy 
depends on a healthcare system’s willingness to pay for each LYG. In the Dutch 
healthcare system, willingness to pay depends on severity of the disease and most 
interventions will be considered cost-effective if costs remain under €40.000/LYG.(36) In 
the UK and US a threshold of $50.000/LYG (approximately €40.000/LYG) is commonly 
used in cost-effectiveness analyses for cancer screening. However, thresholds over 
$50.000/LYG can also be justified.(37) 
 
Our sensitivity analysis confirmed the finding of other studies that the assumed benefit 
(LYG) from LS surveillance has a tremendous effect on ICERs, especially LYG assumed for 
relatives.(12, 16, 17, 23, 24, 27) The benefit of LS surveillance programs for relatives that 
we estimated from literature ranged from 0.40 LYG to 16.74 LYG per relative (Table 1 
and Table S1). These extreme differences reflect the impact of assumptions made on 
uncertain parameters such as CRC risk for LS carriers, the method and risk reduction of 
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LS surveillance and assumed adherence to LS surveillance programs. In our base case 
analysis we used the median of all estimations from literature to attain plausible 
estimates. In our one-way sensitivity analyses we considered the full range of estimates 
from the literature, which resulted in ICERs well within currently accepted thresholds for 
cost-effectiveness. Specifically, all ICERs remained under €13.000/LYG. 
 
LS screening in CRC patients ≤70 years of age identified over three times as many LS 
index patients as only screening CRC patients ≤50 years of age. Also, LS carriers among 
family members of these index patients were identified. We found a median of 3 
relatives that were tested for each index patient. However, there was a very wide range 
from 1-37 relatives that were tested per index patient for a total of 140 relatives. 
Interestingly, in our study over three times as many LS carriers were identified among 
relatives of CRC patients 51-60 years of age compared with the other age categories. This 
difference was partly caused by a very large familiy with 37 relatives tested and 16 LS 
carriers identified, which we may consider as a statistical outlier. Furthermore, the 51-60 
years age group contained 1.5 times as many first degree relatives eligible for genetic 
testing compared with index patients ≤50 years of age and had a higher prevalence of LS 
among tested relatives compared with the 61-70 years age category. An older age of 
siblings from 61-70 year old CRC patients compared with siblings from younger CRC 
patients might explain this difference in LS prevalence, due to the reduced life 
expectancy of LS carriers. Our study may still underestimate the number of LS patients 
ultimately detected among relatives. Relatives currently refraining from targeted 
mutation analysis as well as minors not yet eligible for genetic testing could request 
genetic testing at a later time. Also, CRC patients suspected of LS who currently refrained 
from genetic testing might opt for MMR gene sequencing in the future, thereby further 
increasing the identification of LS carriers among CRC patients and their relatives. 
Further studies are necessary on these issues. 
 
Our results are in line with previous studies using decision-analytic models, in which LS 
screening by only IHC testing or analysis for MSI for CRC patients >50 years of age was 
found to be cost-effective.(16, 17, 26, 27) In one study LS screening of CRC patients ≤60 
years of age led to an ICER of $33.800/LYG (€25.000/LYG) compared with screening 
patients ≤50 years of age. Expanding the age limit for LS screening to CRC patients ≤70 
years of age resulted in an ICER of $44.200/LYG (€33.000/LYG).(16) In contrast, a recent 
Dutch study found an ICER of only €2.703 for LS screening in CRC patients ≤70 years of 
age compared with LS screening of CRC patients ≤50 years of age.(26) However, this 
study did not include costs for gynaecological surveillance. Furthermore, LYG for relatives 
in their study was 6.9 to 7.22 years which is higher than assumed in other studies on 
cost-effectveness of LS screening. Interestingly, the assumed incidence of CRC in LS 
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carriers was higher than in other studies, which accounts for their high estimate of LYG 
per relative tested compared to other recent studies on cost-effectiveness of LS 
screening. Since we used the median of all estimates for LS benefit from the current 
literature, our ICERs are in between those found by Sie et al. and those found by recent 
studies assuming benefit for LS carriers among relatives under 1 LYG. 
 
Sensitivity of the revised Bethesda guidelines was 74% in our cohort. In previous 
literature, the sensitivity of these guidelines was 72-88%.(19) To assess cost-
effectiveness of age-targeted LS screening compared with the revised Bethesda 
guidelines, we assumed only 26% of CRC patients in our cohort fulfilled the revised 
Bethesda guidelines. We assumed 100% adherence to the revised Bethesda guidelines, 
while in clinical practice molecular diagnostics for LS may be performed in only 11-14% 
of the patients fullfilling these guidelines.(11, 38) In a previous study, low rates of failure 
to apply the revised Bethesda guidelines made LS screening by molecular diagnostics the 
preferred strategy.(16) In our study, the ICER for LS screening among CRC patients ≤70 
years of age compared with testing according to the revised Bethesda guidelines 
remained <€13.000/LYG. Age-targeted LS screening may be much easier and therefore 
even more cost-effective to implement in clinical practice than clinical criteria based on 
family history. 
 
LS screening without any age cut-off is presumed to further increase benefit for LS 
carriers. US guidelines recommended LS screening of all CRC patients by IHC or MSI 
analysis as a possible screening strategy.(18) However, it is unclear whether the benefit 
of universal LS screening will come at acceptable costs. In our population-based cohort, 
the prevalence of LS decreased with increasing age of CRC diagnosis. Recently, universal 
tumor testing for LS was not found to be cost-effective by a model constructed by Barzi 
et al.(22) Interestingly, the combination with predictive models was found to be cost-
effective, however only in case of available family history which is known to be an 
important clinical challenge. In line with these findings, a German research group also 
concluded that the most cost-effective strategy involved family-history assessment.(25) 
A recent international validation study confirmed the validity and potential clinical 
usefulness of prediction models to direct testing.(39) 
 
Strengths of this study are the use of real life data of index patients and their relatives, 
inclusion of hypermethylation analysis in the diagnostic work-up, our detailed analysis of 
diagnostic costs, and inclusion of gynaecological surveillance. To our knowledge this 
study is the first cost analysis for LS screening using cost data and family data directly 
derived from a prospective population-based cohort of CRC patients. In contrast to 
studies that fully rely on assumptions in cost-effectiveness models, we aimed to stay 
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close to prospectively collected data. Furthermore, minimal cost savings by CRC 
prevention were used in the calculations. In practice, cost savings from LS screening are 
likely to be much higher. 
 
This study also has several limitations. First, we did not correct LYG for quality of life. As 
posed by some, being identified as LS carrier might not have an impact on quality of life 
and it has been suggested that it is not necessary to include quality of life in cost-
effectiveness analyses of life saving strategies.(40, 41) However, two previous cost-
effectiveness analyses of LS screening did find an impact on the ICER by including quality 
of life.(17, 42) Secondly, costs and benefit from surveillance for extracolonic cancers 
other than gynaecological cancers were not included in our analyses, since these are not 
generally recommended and the actual benefit of such surveillance is unclear. We also 
did not include costs for prophylactic colectomy or aspirin chemoprevention. The use of 
chemoprevention by aspirin in LS carriers is not yet implemented as results of the CAPP3 
study are pending.(43) Third, we did not perform a full probabilistic sensitivity analysis. 
Furthermore, in this study we did not evaluate cost-effectiveness of MSI analysis and IHC 
alone. In previous studies, LS screening by IHC alone was found to be more cost-effective 
than LS screening by MSI analysis alone or MSI analysis and IHC combined.(16, 17) 
Finally, in this study we did not include the use of prediction models for LS detection, 
since detailed family history was not available from all patients. MMRpro, MMRpredict 
and PREMM1,2,6 have been proposed as prescreening tools for LS.(44-46) It has been 
suggested that a combined strategy using IHC and prediction models among CRC patients 
<70 years of age improves the cost-effectiveness of LS detection.(22, 47) Prediction 
models may exclude CRC patients with a minimal risk of having LS from molecular 
diagnostics. Further research should therefore focus on validation of prediction models 
in population-based cohorts and evaluate the combination with molecular testing for LS. 
 
In conclusion, routine screening for LS in CRC patients up to 70 years of age is a cost-
effective strategy according to currently accepted standards with important clinical 
benefits for LS carriers among CRC patients and their relatives. Our findings support the 
recent recommendation for LS screening by analysis of MSI or IHC and MLH1 
hypermethylation in all CRC patients ≤70 years of age.(18, 19) 
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SUPPLEMENTAL MATERIAL 
 
Table S1. Data on Life years gained (3% discounted) by index patients and relatives 
 Females Males Source 
Index patients 0,191 0,092 Ladabaum et al 2011 
 0,14 0,14 Calculated from Sie et al 2014 
 0,53 0,53 Calculated from Snowsill et al 2014 
 0,79 0,79 Calculated from Ramsey et al 2003 
 0,79 0,79 Calculated from Ramsey et al 2001 
 2,15 2,15 Calculated from Kievit et al 2005 
Median 0,66 0,66  
    
Relatives 0,40 0,47 Calculated from Severin et al 2015 
 0,49 0,51 Ladabaum et al 2011 
 0,63 0,63 Barzi et al 2015 
 0,64 0,64 Calculated from Snowsill et al 2014 
 1,07 1,07 Mvundura et al 2010 
 2,83 2,83 Calculated from Kievit et al 2005 
 3,58 3,58 Calculated from Vasen et al 2010 
 6,91 6,91 Calculated from Syngal et al 1998 
 8,58 8,58 Calculated from Sie et al 2014 
 16,02 16,02 Calculated from Ramsey et al 2001 
 16,74 16,74 Calculated from Ramsey et al 2003 
Median 2,83 2,83  
If adherence to LS surveillance programs was not included in the reported LYG, we corrected LYG by assuming 
adherence of 80% for both index patients and LS carriers among their relatives. 
 
 
Table S2. Cost data in 2013 euros for Lynch syndrome diagnostics and surveillance 
 Cost Source 
Lynch syndrome diagnostics†   
Analysis for microsatellite instability € 89 Dept. of Pathology, Erasmus MC 
IHC testing for MMR protein expression € 135 Dept. of Pathology, Erasmus MC 
MLH1 hypermethylation analysis € 99 Dept. of Pathology, Erasmus MC 
Genetic counseling for index patients € 298 Dept. of Clinical Genetics, Erasmus MC 
Genetic counseling for relatives €167 Dept. of Clinical Genetics, Erasmus MC 
MMR gene sequencing (per gene) € 538 Dept. of Clinical Genetics, Erasmus MC 
Targeted mutation analysis for relatives € 304 Dept. of Clinical Genetics, Erasmus MC 
   
Lynch syndrome surveillance   
Surveillance colonoscopy including polypectomy € 393 Goede et al 2013 
Treatment of complications after colonoscopy € 1.250 Goede et al 2013 
Treatment cost of stage I CRC (first 12 months) € 12.100 Goede et al 2013 
Transvaginal ultrasound € 100 Ladabaum et al 2011 
Endometrial biopsy € 204 Ladabaum et al 2011 
Prophylactic hysterectomy and salpo-oophorectomy € 14.920 Ladabaum et al 2011 
IHC: Immunohistochemistry; MMR: Mismatch repair; CRC: Colorectal cancer. 
† Costs were determined following the microcosting method and included costs of employment, material, 
equipment and overhead 
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Table S3. Incremental costs in 2013 euro for Lynch syndrome screening in CRC patients ≤70 years of age and 
the revised Bethesda guidelines 
Colorectal cancer patients (n=1117) Revised Bethesda guidelines Total ≤70 years 
Lynch syndrome diagnostics   
CRC patients   
 Molecular diagnostics € 65.681  € 259.831  
 Genetic counseling € 7.447  € 12.510  
 MMR gene sequencing € 16.134  € 37.646  
Relatives   
 Genetic counseling € 16.345  € 23.183  
 Targeted mutation analysis € 29.490  € 41.955  
   
Lynch syndrome surveillance   
Colonoscopy surveillance   
 Index patients € 46.184  € 60.211  
 Relatives € 223.039  € 297.385  
Gynaecologic surveillance and prophylactic surgery   
 Index patients € 51.121  € 55.651  
 Relatives € 261.989  € 325.374  
Savings by prevention of CRC - € 55.307   - € 73.743  
   
Total costs (minus savings) € 662.123  € 1 040.005  
Total life years gained 154.4 205.9 
Costs per life year gained Reference € 7.341 
 
 
 
Figure S1. One-way sensitivity analysis for the ICER of routine screening for Lynch syndrome in colorectal 
cancer patients ≤70 years compared with Lynch syndrome screening in colorectal cancer patients ≤60 years of 
age. 
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ABSTRACT 
 
Purpose To assess cost-effectiveness of routine screening for Lynch syndrome (LS) in 
endometrial cancer (EC) patients ≤70 years of age. 
Methods Consecutive EC patients ≤70 years of age were screened for LS by analysis of 
microsatellite instability, immunohistochemistry and MLH1 hypermethylation. Costs and 
health benefit in life years gained (LYG) included surveillance for LS carriers among EC 
patients and relatives. We calculated incremental cost-effectiveness ratios (ICERs) 
comparing LS screening among EC patients ≤70 years with ≤50 years and the revised 
Bethesda guidelines. 
Results Screening for LS in 179 EC patients identified 7 LS carriers; 1 was ≤50 and 6 were 
51-70 years. Per age category 18 and 9 relatives were identified as LS carrier. Screening 
resulted in 74,7 LYG (45,4 and 29,3 LYG per age category). The ICER for LS screening in EC 
patients ≤70 compared with ≤50 years was €5.252/LYG. The revised Bethesda guidelines 
missed 4/7 (57%) LS carriers among EC patients. The ICER for LS screening in EC patients 
≤70 years of age compared with the revised Bethesda guidelines was €6.668/LYG. Both 
ICERs remained <€16.000/LYG in sensitivity analyses. 
Conclusion Routine LS screening in EC patients ≤70 years is a cost-effective strategy, 
allowing colorectal cancer prevention in EC patients and their relatives. 
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INTRODUCTION 
 
Lynch syndrome (LS) is a hereditary cancer syndrome characterized by early onset of 
colorectal cancer (CRC), endometrial cancer (EC) and other extracolonic cancers.(1, 2) 
Over half of the women who develop multiple LS associated cancers will present with a 
gynaecological malignancy, in most cases EC.(3) LS carriers among EC patients are at high 
risk of developing CRC. It is important to identify LS in EC patients, since colonoscopy 
surveillance prevents development of CRC in these patients and their affected family 
members.(4-6) 
 
Tumors from LS patients display certain characteristics: microsatellite instability (MSI) 
and loss of mismatch repair (MMR) protein expression in immunohistochemistry 
(IHC).(7) In cases with loss of MLH1 protein expression, MLH1 hypermethylation analysis 
can be done to distinguish between sporadic MLH1 deficient tumors and tumors likely 
caused by LS.(7) Mean age at CRC diagnosis in LS carriers is 44-61 years, compared with 
69 years in sporadic CRC cases.(8) Recent guidelines recommend routine LS screening by 
analysis of MSI and/or IHC among CRC patients up to 70 years of age.(8, 9) Guidelines for 
LS screening among EC patients, however, are ambiguous. Mean age at EC diagnosis 
among LS carriers is between 48-62 years, compared with 65 years for sporadic cases of 
EC.(8) A European group of experts recommends routine LS screening among EC patients 
up to 70 years of age(9), while an American task force advises an age-cut of 50 years.(8) 
Although several age cut-offs as well as universal LS screening among EC patients have 
been suggested, data on the cost-effectiveness of such strategies are scarce.(10-12) 
Furthermore, only one of these cost-effectiveness analyses calculated effectiveness in 
life years gained and none of these studies included costs and health benefit for relatives 
of LS patients in their analyses. 
 
In 2012 we reported on a population-based cohort of EC patients ≤70 years of age 
routinely screened for LS by analysis of MSI, IHC and MLH1 hypermethylation. A profile 
compatible with LS was detected in 6% of these EC patients and all but one of these 
patients (10/11) were over 50 years of age.(13) In the current study, we used data from 
this population-based cohort including costs and benefit for relatives to assess whether 
routine LS screening among EC patients up to 70 years of age is cost-effective. 
 
 
 
 
 
 
Chapter 5 
68 
METHODS 
 
Subjects and diagnostic work-up 
We used data from a prospective population-based study on the yield of routine 
molecular screening for LS in EC patients up to 70 years of age, described in detail 
previously.(13) In summary, consecutive EC patients ≤70 years of age (n=179) from 8 
Dutch hospitals were routinely screened for LS by analysis of MSI, IHC for MLH1, MSH2, 
MSH6 and PMS2 protein expression. MLH1 hypermethylation analysis was performed in 
cases with loss of MLH1 protein expression. Patients with tumor characteristics suspect 
for LS, i.e. a high degree of MSI and/or absence of MMR protein without MLH1 promoter 
hypermethylation, were offered genetic counselling and germline mutation analysis 
(Figure 1). 
 
Figure 1. Diagnostic work-up to detect Lynch syndrome among endometrial cancer patients ≤70 years. 
MSI: microsatellite instability; MSS: microsatellite stable; MMR: mismatch repair; MSI-High: high degree of MSI; 
EC: endometrial cancer. 
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Patients identified with a pathogenic germline mutation in one of the MMR genes MLH1, 
MSH2, MSH6, or PMS2, or in the EPCAM gene, were labelled index patients. Relatives of 
index patients were offered genetic counselling and targeted mutation analysis via the 
index patients. We registered the number of relatives accepting genetic counselling and 
targeted mutation analysis, the number of LS carriers identified among relatives and 
their age at time of LS diagnosis up to February 2015. This study was approved by the 
Institutional Review Boards of the participating hospitals. 
 
Effectiveness 
Health benefit from LS screening in life years gained (LYG) was calculated, based on the 
number of LS patients detected among EC patients and their relatives. In previous 
studies LS surveillance resulted in 0.15-2.50 LYG for female index patients with CRC and 
0.49 to 32.69 LYG for relatives (Table 1).(14-25) No data is available on LYG by LS 
surveillance for EC index patients. For these patients we therefore used the median of all 
LYG from literature for female index patients with CRC. Similarly, we used the median of 
all reported LYG for relatives for LS carriers that were identified among family members 
of index patients (Table 1). Most studies only reported 3% discounted LYG and if 
undiscounted LYG were reported, we first discounted them by 3% annually 
(Supplementary information, Table S1). For studies that did not include the adherence to 
LS surveillance programs in the reported LYG, we assumed an adherence of 80% for 
index patients as well as LS carriers among their relatives.(16) We assumed that EC 
patients and relatives without a pathogenic mutation identified would not undergo LS 
surveillance. Also, no health benefit or surveillance costs were calculated for deceased 
cases. 
 
Costs 
Detailed direct medical costs for LS diagnostics (i.e. MSI analysis, IHC, MLH1 
hypermethylation analysis, genetic counseling and germline mutation analysis) in EC 
patients and their relatives were calculated using the microcosting method.(26) Cost 
data for PMS2 germline mutation analysis were not available and were assumed to be 
similar to costs for germline mutation analysis of other MMR genes. Total costs for 
routine LS screening, including costs for LS diagnostics, LS surveillance for LS carriers, and 
savings by prevention of CRC development, were determined based on the number of EC 
patients and relatives analyzed. Index patients and relatives were assumed to undergo LS 
surveillance, consisting of colonoscopy with polypectomy every two years, starting at the 
age patients were diagnosed with LS (or at age 25 for younger relatives) up to 75 years of 
age. Additionally, female LS carriers among relatives were assumed to undergo 
gynaecologic surveillance consisting of yearly transvaginal ultrasonography and 
endometrial biopsy from age 35 until prophylactic surgery at 40 years of age. We 
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assumed that 18% of these relatives accepted prophylactic surgery (total abdominal 
hysterectomy and bilateral salpo-oophorectomy).(16) LS carriers not accepting 
prophylactic surgery were assumed to continue yearly gynaecological surveillance up to 
75 years of age. We did not include costs for prophylactic colectomy or aspirin 
chemoprevention, since both are not recommended as standard clinical care by current 
guidelines. All costs for LS surveillance were derived from literature. For cost savings by 
prevention of CRC in surveillance programs, the most conservative estimate (only 
treatment costs for the first 12 months of stage I CRC) was used. Costs for gynaecological 
screening were only available in dollars and were converted to euros using purchasing 
power parity. All costs were converted to price level 2013 using the Dutch consumer 
price index(27) and were discounted by 3% annually. All cost data are summarized in 
Supplemental Table 2. 
 
 
Table 1. Parameters and values used in the cost-effectiveness analysis. 
Parameter Base case value Range Source 
Median age at LS diagnosis    
Index patients 59 IQR 53-62 (13) 
Relatives 46 IQR 36-54 Current study 
Female Relatives 46 IQR 36-57 Current study 
    
LS surveillance†    
Discounted life years gained    
  Index patients‡ 0.68 0.13-2.14 (15, 16, 18, 19, 21, 22) 
  Female relatives 2.80 0.40-17.82 (14-25) 
  Male relatives 2.80 0.47-17.82 (14-25) 
Interval between colonoscopies (years) 2 1-2 (8, 9) 
Complication rate of colonoscopy 0.0024  (28) 
Acceptance of prophylactic gynaecological 
surgery 
0.18 0.03-0.25 (16) 
    
CRC risk and risk reduction    
Lifetime risk of developing CRC for LS 
carriers 
0.25 0.25-0.70 (5, 6, 23, 29) 
Reduction in CRC risk by LS surveillance 0.56 0.56-0.70 (5, 6, 30) 
LS: Lynch syndrome; CRC: Colorectal cancer 
† Life years gained were discounted by 3% annually 
‡ Health benefit for CRC index patients was used for index patients, since no data are available on LYG for index 
patients with endometrial carcinoma 
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Revised Bethesda guidelines 
For EC patients who received genetic counselling, a detailed family history was obtained, 
and one clinical geneticist (AW) assessed if these patients fulfilled the revised Bethesda 
guidelines. Family history for patients who did not receive genetic counselling was not 
available. We assumed that these patients would not fulfil the revised Bethesda 
guidelines, biasing our analysis against age-targeted LS screening. 
 
Cost-effectiveness analyses 
Incremental costs and health benefit were calculated for LS screening among EC patients 
using an age cut-off of 70 years compared with an age cut-off of 50 years. The 
incremental cost-effectiveness ratio (ICER) indicates the additional costs per LYG. We 
also calculated the ICER of routine LS screening in EC patients ≤70 years of age compared 
with a screening strategy according to the revised Bethesda guidelines. We performed 
one-way sensitivity analyses in order to test the robustness of the ICERs. Costs were 
assumed to range from 0.5 to 2 times as much as calculated. Ranges for all other 
parameters were based on literature (Table 1). 
 
 
RESULTS 
 
Routine LS screening among 179 EC patients identified 11 patients (6.1%) suspected of 
having LS (Figure 1). All patients suspected of having LS received genetic counselling. 
Consecutive germline mutation analysis was accepted by 10/11 patients and finally 
identified 7 LS patients (3.9%). 
 
Effectiveness of screening 
The median age of EC patients was 61 years (IQR 57-66); 15 EC patients were ≤50 years 
and 164 patients were 51-70 years of age. The prevalence of LS decreased was 6.7% 
(1/15) in EC patients ≤50 years of age and 3.7% (6/164) in EC patients 51-70 years of 
age.(Table 2). Per index patient a median of 3 (IQR 2-8) relatives accepted genetic 
counselling and germline mutation analysis. In total, germline mutation analysis was 
accepted by 73 relatives, resulting in identification of 27 additional LS carriers. 
Surveillance of LS carriers among EC patients ≤70 years of age and their relatives 
amounted in a total of 74.7 LYG. Only a small portion of the health benefit was attributed 
to LS surveillance among index patients (4.8 LYG vs. 69.9 LYG for relatives). Although LS 
screening among EC patients ≤50 years of age only identified a single LS carrier, a higher 
benefit was found for this group than for screening among the older age category (44.8 
LYG vs. 25.2 LYG). The high amount of LYG found in the younger age group was caused 
by a large number of 50 relatives tested, identifying 18 LS carriers. 
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Table 2. Number of patients screened and detection of Lynch syndrome among EC patients and relatives 
Endometrial cancer patients (n=179) <50 years 
(n=14) 
51-70 years 
(n=165) 
Total 
LS diagnostics in EC patients    
 Analysis for MSI and IHC 14 165 179 
 MLH1 hypermethylation analysis 0 32 32 
 EC patients suspected of having LS 1 10 11 
 Genetic counseling 1 10 11 
 Germline mutation analysis 1 9 10 
 Genes tested in EC patients or FDR 1 11 12 
  LS index patients identified 1 6 7 
    
LS diagnostics in relatives    
Relatives accepting genetic counseling 50 23 73 
Germline mutation analysis 18 9 27 
  LS carriers identified among relatives 11 7 18 
    
Life years gained    
LYG by index patients    
LYG by male relatives 0.7 4.1 4.8 
LYG by female relatives 19.6 5.6 25.2 
Total LYG (index and relatives) 25.2 19.6 44.8 
Numbers may not add up due to rounding 
LS; Lynch syndrome, EC: Endometrial cancer; MSI: Microsatellite instability; HC: Immunohistochemistry; FDR: 
First degree relative 
 
Costs and cost-effectiveness 
Total costs for LS screening increased from €150.817 (€7.938 per LS carrier detected) for 
EC patients ≤50 years of age to €304.442 (€8.954 per LS carrier detected) for EC patients 
≤70 years of age. LS screening for EC patients ≤70 years of age had an ICER of €5.252/LYG 
compared with screening patients up to 50 years of age (Table 3). In one-way sensitivity 
analysis the assumed LYG for LS carriers among relatives impacted the ICER the most. 
The ICER for screening EC patients ≤70 years of age compared with screening patients 
with EC diagnosed ≤50 years of age never exceeded €13.000/LYG (Figure 2). 
 
Revised Bethesda guidelines 
LS screening according to the revised Bethesda guidelines would have identified 3/7 
(43%) index patients and 22/27 (81%) relatives. Using favorable assumptions, total cost 
for this strategy were €193.066 (€7.723 per LS carrier detected), with a total health 
benefit of 58.0 LYG. The ICER for routine LS screening in CRC patients ≤70 years 
compared with the revised Bethesda guidelines was €6.668/LYG. In sensitivity analysis 
this ICER never exceeded €16.000/LYG. 
 
Cost-effectiveness of Lynch syndrome screening in endometrial cancer patients 
73 
5 
Figure 2. One-way sensitivity analysis for the ICER of routine screening for Lynch syndrome in endometrial 
cancer patients using an age cut-off of 70 years compared with an age cut-off of 50 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Incremental costs in 2013 euro for Lynch syndrome screening in EC patients of different age 
categories 
 <50 years 61-70 years Total 
Lynch syndrome diagnostics    
Endometrial cancer patients    
 Molecular diagnostics € 3.142 € 40.212 € 43.354 
 Genetic counseling € 298 € 2.979 € 3.276 
 Germline mutation analysis € 538 € 5.916 € 6.454 
Relatives    
 Genetic counseling € 8.172 € 3.836 € 12.008 
 Targeted mutation analysis € 15.201 € 6.993 € 22.194 
    
Lynch syndrome surveillance    
Colonoscopy surveillance    
 Index patients € 3.883 € 15.597 € 19.481 
 Relatives € 64.902 € 36.507 € 101.410 
 Savings by prevention of colorectal 
cancer  
- € 18.240 - € 10.260 - € 28.499 
Gynaecologic surveillance and 
prophylactic surgery in relatives 
€ 72.920 € 51.845 € 124.765 
    
Total costs (minus savings) € 150.817 € 153.625 € 304.442 
Total life years gained 45.4 29.3 74.7 
Costs per life year gained reference € 5.252 - 
Numbers may not add up due to rounding  
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DISCUSSION 
 
Based on this population-based cohort of EC patients routine screening for LS in EC 
patients ≤70 years of age by analysis of MSI, IHC and MLH1 hypermethylation is a cost-
effective strategy. In sensitivity analysis, the ICER for routine LS screening among EC 
patients up to 70 years of age compared to EC ≤50 years of age remained <€13.000/LYG 
(<$15.000/LYG). For life-saving interventions a threshold of €40.000/LYG (or 
$50.000/LYG) is commonly accepted, and some authors advocate even higher 
thresholds.(31, 32)  
 
In this cost-effectiveness analysis, we used the median of all estimates from literature for 
the health benefit that results from LS screening. Previous studies, as well as our own 
sensitivity analysis, showed that assumptions for health benefit in relatives have a 
tremendous effect on the ICER.(15-19) Since there are no estimates available for health 
benefit of EC index patients, we used the median of all estimates for CRC index patients. 
However, we expect that index patients with EC will benefit more from LS surveillance 
than index patients with CRC, since mortality rate is higher in LS patients diagnosed with 
CRC than in LS patients diagnosed with EC.(33) 
 
Most of the relatives tested for LS in our study were related to the one index patient ≤50 
years of age. In this family 50 relatives were tested compared to a total of 23 relatives for 
all index patients >50 years of age together. However, since the index patient ≤50 years 
and all her relatives were our reference group, the large number of relatives tested in 
this family did not impact the ICER. The focus of our study lies on the incremental costs 
and benefit for LS screening among EC patients 51-70 years of age and their relatives. For 
these EC patients, between 1 and 11 relatives accepted germline mutation analysis. 
Previous studies on cost-effectiveness of LS screening among CRC patients have assumed 
that a total of 2-8 relatives would be tested per index patient.(16, 17, 21) Among the EC 
patients in our cohort aged 51-70 years this would result in a total of 12-48 relatives 
tested for LS. The total of 23 relatives accepting germline mutation analysis we found in 
this age group is at the lower half of these estimates. In time, far more LS carriers might 
be identified among relatives of the index patients in our study. Relatives refraining from 
germline mutation analysis and minors not yet eligible for genetic testing, could still be 
tested at a later time and enroll in LS surveillance programs. This would increase the 
costs of our analyses, however the increased benefit in LYG would likely lead to lower 
ICERs. 
 
Only a few studies have been published on cost-effectiveness of LS screening among EC 
patients. All of these studies concluded that some form of LS screening among EC 
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patients was cost-effective.(10-12) However, none of these studies included health 
benefit for relatives; one study calculated costs/LYG for index patients, another 
calculated costs/index patient detected, and the third study calculated costs/possible 
index patient detected. Two studies found that LS screening by IHC among all EC patients 
was cost-effective compared with clinical criteria, the Amsterdam criteria and the SGO 
criteria respectively.(10, 12) In contrast, Kwon et al found that LS screening by IHC 
analysis of all EC patients who had one or more first degree relatives with a LS associated 
cancer, was more cost-effective than routine IHC analysis among EC patients using an 
age cut-off of 50 or 60 years.(11) In our study, we used a higher age cut-off of and almost 
half of the LS carriers we identified among EC patients, were over 60 years of age. Using 
favourable assumptions for the revised Bethesda guidelines, the ICER for LS screening 
among EC patients up to 70 years of age compared with these guidelines remained 
<€16.000/LYG. We believe that an age cut-off will be much easier to use in clinical 
practice, since previous research among CRC patients showed that clinical criteria for LS 
screening based on family history are poorly applied in clinical practice.(34, 35) 
 
In our study analysis for MSI as well as IHC for loss of mismatch repair protein was 
performed for all patients. In studies for LS screening among CRC patients, IHC analysis 
alone was more cost-effective than LS screening by MSI analysis or analysis of MSI and 
IHC combined.(16, 17) Omitting MSI analysis from our diagnostic work-up would most 
likely also result in a lower ICER. In CRC patients, combining IHC analysis and prediction 
models for LS may further increase the cost-effectiveness of LS screening.(36) However, 
such prediction models are not well applicable on EC patients.(37) 
 
LS screening among EC patients up to 70 years of age identified 7 times more index 
patients than only screening EC patients up to 50 years of age. Screening all EC patients 
for LS regardless of age is proposed by some authors and will undoubtedly detect even 
more LS carriers.(38) Little is known, however, about the ultimate costs and benefit of 
universal LS screening among EC patients. One study reported an ICER of $648.494 
(>€500.000) for screening all EC patients for LS by IHC analysis compared with IHC 
analysis for EC patients with at least one first degree relative with a LS associated 
cancer.(11) However, only LYG for index patients were included in this analysis, and not 
the health benefit for relatives, which has a far greater impact on ICERs. 
 
Current guidelines recommend routine LS screening for CRC patients up to 70 years of 
age.(8, 9) For EC patients, however, LS screening is ambiguously recommended with age 
cut-offs of 50 years or 70 years. In clinical practice EC patients are usually not screened 
for LS, even if they fulfill the revised Bethesda guidelines.(39, 40) Therefore, in clinical 
practice, many LS carriers among EC patients will remain undetected. Identifying these LS 
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carriers can greatly improve their survival and in an even larger extend improve survival 
of their relatives.  
 
In our study benefit of LS screening was based on the decrease in mortality by LS 
surveillance. We only used conservative estimates for the cost saved by a decrease in 
CRC morbidity. We did not account for the gained quality of life by the reduction of 
morbidity. Furthermore, the decrease in mortality and morbidity by LS surveillance will 
impact cost-effectiveness by allowing LS patients to continue their daily activities 
including working. Additional strategies such as informing patients on signs and 
symptoms of cancer could further contribute to early diagnosis of cancer, thereby 
contributing to the cost-effectiveness of LS screening. Also, encouraging LS carriers to 
make lifestyle choices such as not smoking could increase the benefit of LS surveillance 
programs. Finally, aspirin treatment to prevent development of cancer would add to the 
costs of LS screening, but may further increase its benefit. We did not include these 
strategies in our analysis, since there are no exact data on their benefit. 
 
To our knowledge, this study is the first cost-effectiveness analysis for LS screening 
among EC patients that includes costs and health benefit for relatives. Other strengths of 
this study are the detailed analysis of costs, the use of data from a population-based 
cohort prospectively screened for LS, the inclusion of MLH1 hypermethylation analysis in 
LS diagnostics, and the use of conservative estimates if assumptions were needed. 
 
Our study also has several limitations. First, the data set was small with only 7 LS index 
patients and all patients from a Dutch population, which may not be representative for 
other populations. However, in a recent study among American EC patients the 
prevalence of LS in patients with endometroid type EC without an age cut-off was at 
least 3,89%, which corresponds well with the LS prevalence in our cohort (7/179, 
3,9%).(41) Secondly, we did not include LS surveillance for extracolonic cancers other 
than gynaecological cancers in the cost-effectiveness analysis, since health benefit from 
such surveillance is still unclear. For LS carriers, lifetime risk of developing other LS-
associated cancers such as small-bowel cancer and gastric cancer are below 20%, while 
lifetime risks for CRC and EC are up to 70%.(9) Furthermore, we only performed one-way 
sensitivity analyses, as opposed to full probabilistic sensitivity analyses. Also, it is unclear 
whether all studies from which we used the number of LYG corrected for other causes of 
death. We use the median of all LYG from literature for our base case scenario. Recently, 
the assumptions from Mvundura et al. were updated by accounting for death from other 
causes amongst other recalculations. Grosse et al found that accounting for other causes 
of death specifically resulted in a 5% lower number for LYG.(25) However, if we assumed 
5% lower LYG in our study, all ICERs would still remain <€17.000/LYG and therefore well 
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below the currently accepted standards for cost-effectiveness. Finally, LYG were not 
corrected for quality of life, as this has been reported to be unnecessary for benefit of LS 
detection.(42, 43) 
 
In conclusion, routine screening for LS by analysis of MSI, IHC and MLH1 
hypermethylation in EC patients up to 70 years of age is a cost-effective strategy 
according to currently accepted standards, allowing prevention of CRC in EC patients and 
their relatives. Implementation in clinical practice should be considered. In the 
Netherlands, routine screening for LS using IHC is now being implemented. Further 
research should focus on the cost-effectiveness of LS screening in larger cohorts of EC 
patients including routine LS screening without an age cut-off. 
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SUPPLEMENTAL MATERIAL 
 
Table S1. Data on Life years gained (3% discounted) by index patients and relatives 
 Females Males Source 
Index patients 0,191  Ladabaum et al 2011 
 0,13  Calculated from Sie et al 2014 
 0,54  Calculated from Snowsill et al 2014 
 0,82  Calculated from Ramsey et al 2003 
 0,82  Calculated from Ramsey et al 2001 
 2,14  Calculated from Kievit et al 2005 
Median 0,68   
    
Relatives 0,40 0,47 Calculated from Severin et al 2015 
 0,49 0,51 Ladabaum et al 2011 
 0,63 0,63 Barzi et al 2015 
 0,68 0,68 Calculated from Snowsill et al 2014 
 0,80 0,80 Mvundura et al 2010 
 2,80 2,80 Calculated from Kievit et al 2005 
 3,82 3,82 Calculated from Vasen et al 2010 
 7,36 7,36 Calculated from Syngal et al 1998 
 8,09 8,09 Calculated from Sie et al 2014 
 17,05 17,05 Calculated from Ramsey et al 2001 
 17,82 17,82 Calculated from Ramsey et al 2003 
Median 2,80 2,80  
 
 
 
Table S2. Cost data in 2013 euros for Lynch syndrome diagnostics and surveillance 
 Cost Source 
Lynch syndrome diagnostics†   
 Analysis for microsatellite instability € 89 Dept. of Pathology, Erasmus MC 
 IHC testing for MMR protein expression € 135 Dept. of Pathology, Erasmus MC 
 MLH1 hypermethylation analysis € 99 Dept. of Pathology, Erasmus MC 
 Genetic counseling for index patients € 389 Dept. of Clinical Genetics, Erasmus MC 
 Genetic counseling for relatives € 256 Dept. of Clinical Genetics, Erasmus MC 
 MMR gene sequencing (per gene) € 538 Dept. of Clinical Genetics, Erasmus MC 
 Targeted mutation analysis for relatives € 304 Dept. of Clinical Genetics, Erasmus MC 
   
Lynch syndrome surveillance   
 Surveillance colonoscopy including polypectomy € 393 Goede et al 2013 
 Treatment of complications after colonoscopy € 1.250 Goede et al 2013 
 Treatment cost of stage I CRC (first 12 months) € 12.100 Goede et al 2013 
 Transvaginal ultrasound € 100 Ladabaum et al 2011 
 Endometrial biopsy € 204 Ladabaum et al 2011 
 Prophylactic hysterectomy and salpo- 
 oophorectomy 
€ 14.920 Ladabaum et al 2011 
IHC: Immunohistochemistry; MMR: Mismatch repair; CRC: Colorectal cancer. 
† Costs were determined following the microcosting method and included costs of employment, material, 
equipment and overhead 
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ABSTRACT 
 
Lynch syndrome (LS) is a hereditary cancer predisposition caused by inactivating 
mutations in DNA mismatch repair (MMR) genes. Mutations in the MSH6 DNA MMR 
gene account for approximately 18% of LS cases. Many LS-associated sequence variants 
are nonsense and frameshift mutations that clearly abrogate MMR activity. However 
missense mutations whose functional implications are unclear are also frequently seen 
in suspected-LS patients. To conclusively diagnose LS and enroll patients in appropriate 
surveillance programs to reduce morbidity as well as mortality, the consequences of 
these variants of uncertain clinical significance (VUS) must be defined. We present an 
oligonucleotide-directed mutagenesis screen for the identification of pathogenic MSH6 
VUS. In the screen, the MSH6 variant of interest is introduced into mouse embryonic 
stem cells by site-directed mutagenesis. Subsequent selection for MMR-deficient cells 
using the DNA damaging agent 6-thioguanine (6TG) allows the identification of MMR 
abrogating VUS because solely MMR-deficient cells survive 6TG exposure. We 
demonstrate the efficacy of the genetic screen, investigate the phenotype of 26 MSH6 
VUS and compare our screening results to clinical data from suspected-LS patients 
carrying these variant alleles. 
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INTRODUCTION 
 
Lynch syndrome (LS) is an autosomal dominant predisposition to a variety of 
malignancies at a young age, mainly colorectal cancer (CRC) and endometrial cancer 
(EC).(1) It is caused by inactivating germline mutations in the DNA mismatch repair 
(MMR) genes MLH1, MSH2, MSH6 or PMS2, or a deletion in the 3’ region of the EPCAM 
gene that affects MSH2 expression.(2-6) 
 
The DNA MMR system is essential for the fidelity of DNA replication. Its primary function 
is the correction of base-base mismatches and insertion-deletion loops that may arise 
during DNA replication. Base-base mismatches are recognized by the MSH2-MSH6 
heterodimer while MSH2-MSH3 detects loops of unpaired bases. Following mismatch 
binding, the MSH heterodimers recruit another heterodimer, MLH1-PMS2, to coordinate 
removal and resynthesis of the error-containing strand.(7-9) A second function of the 
DNA MMR system is to mediate the toxicity of certain DNA damaging agents such as 
methylating agents and thiopurines. These DNA damaging agents create adducts in the 
genome that give rise to mismatches when replicated. The DNA MMR system recognizes 
the mismatches but will remove the incorporated nucleotide rather than the lesion itself, 
creating a repetitive cycle of nucleotide incorporation and deletion that ultimately leads 
to DNA breakage and cell death.(10, 11) In the absence of MMR, cells tolerate 
methylation damage, but consequently show high levels of DNA damage-induced 
mutagenesis on top of a strongly elevated level of spontaneous mutagenesis.(12) 
 
LS patients inherit a functional and a mutant copy of one of the DNA MMR genes. For 
cells to become MMR-deficient and develop a mutator phenotype that accelerates 
carcinogenesis, somatic loss of the wild-type allele is required.(13) Microsatellite 
instability (MSI), i.e., length alterations of repetitive sequences like (CA)n or (A)n, and loss 
of immunohistochemical staining (IHC) for MMR proteins are considered hallmarks of LS 
tumors. Analysis of MSI and IHC on tumor tissue can identify patients who may suffer 
from LS. For a definitive LS diagnosis, however, sequence analyses must reveal a 
pathogenic germline mutation in one of the DNA MMR genes or the 3’ region of 
EPCAM.(14, 15) Many LS-associated sequence variants are nonsense and frameshift 
mutations that clearly truncate the protein and unambiguously abrogate MMR activity. 
Missense mutations that only alter a single amino acid are also frequently identified in 
suspected-LS patients. The functional implications of these variants are less clear. 
Consequently, the diagnosis of suspected-LS patients carrying missense variants is 
difficult in the absence of clear segregation and functional data. As long as the 
phenotype of these variants of uncertain significance (VUS) is unclear, non-carriers 
cannot safely be discharged from burdensome surveillance programs.(16) Surveillance 
programs have proven to significantly reduce morbidity and mortality in LS patients (1, 
17, 18), but pose unnecessary psychological and physical stress on carriers of innocent 
VUS as well as pressure on preventive healthcare. Therefore, techniques that 
characterize MMR gene VUS and enable the identification of individuals at risk are 
urgently needed. 
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While in the past primarily MSH2 and MLH1 were sequenced to identify LS-causing 
mutations, in recent years MSH6 has been gained fame for causing LS due to the 
advancement of DNA sequencing. However, MSH6 mutation carriers can be difficult to 
diagnose because they may not entirely fulfill the criteria for LS diagnosis: their age at 
cancer onset is generally later than for MLH1 and MSH2 mutation carriers, and their 
tumors occasionally stain for MSH6 and have no or low MSI.(19-21) We therefore 
extended the applicability of the oligonucleotide-directed mutagenesis screen we 
recently described for the identification of pathogenic MSH2 variants to MSH6 
variants.(22) The genetic screen uses oligonucleotide-directed gene modification (oligo 
targeting) (23) to introduce variant codons into the endogenous Msh2 gene of mouse 
embryonic stem cells (mESCs) and subsequently identifies pathogenic variants by 
selecting for cells that are resistant to the thiopurine 6-thioguanine (6TG). Here we 
present the applicability of this screen for the characterization of MSH6 VUS. 
 
 
RESULTS 
 
Genetic screen for the identification of pathogenic MSH6 mutations 
The oligonucleotide-directed mutagenesis screen takes a four step approach to the 
identification of pathogenic MSH6 mutations (Figure 1): 1) site-directed mutagenesis to 
introduce the variant of interest into a subset of Msh6+/- mESCs, 2) selection for cells that 
consequently lost MMR capacity, 3) PCR analysis to exclude cells that lost MMR capacity 
due to loss of the Msh6+ allele (loss of heterozygosity events), 4) sequence analysis to 
confirm the presence of the planned mutation in the MMR-deficient cells. 
 
mESCs provide a good study model because the human and mouse MSH6 amino acid 
sequences share over 86% identity (Figure S1) and mouse models can be made from 
these cells if VUS need to be studied in vivo. Msh6+/- mESCs only contain one wild type 
Msh6 allele (Msh6+); the other allele was disrupted by a puromycin-resistance gene and 
therefore inactivated (Msh6-).(24) Hence introduction of a specific mutation into the one 
active Msh6 allele will lead to expression of solely the variant protein and allow 
immediate investigation of its phenotype. To achieve this, Msh6 was site-specifically 
mutated by oligo targeting, a gene modification technique that uses short single-
stranded locked-nucleic-acid-modified DNA oligonucleotides (LMOs) (with either sense 
or antisense orientation) to substitute a single base pair at a desired location. LMO-
directed base-pair substitution can be achieved at an efficiency of 10-3; thus, about 1 in 
every 1000 LMO-exposed Msh6+/- mESCs will contain the desired mutation.(23) To 
determine whether the substitution abrogated Msh6 activity and this subset of cells 
consequently lost MMR activity, LMO-exposed mESCs were treated with 6TG. The 
thiopurine DNA damaging agent 6TG is highly toxic to MMR-proficient but only 
moderately toxic to MMR-deficient cells.(11) Therefore, the appearance of colonies that 
survived mild 6TG selection is indicative for loss of MMR capacity. Loss of MMR capacity 
may arise due to the introduced mutation or due to loss of heterozygosity events that 
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caused loss of the functional Msh6 allele. To exclude the latter from further investigation, 
a PCR that detected the presence of both the disrupted and non-disrupted Msh6 alleles 
was performed.(24) 6TG-resistant colonies that maintained both Msh6 alleles were 
sequenced to confirm the presence of the planned mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Oligonucleotide-directed mutagenesis screen for the detection of pathogenic MSH6 variants. 
(A) Msh6+/- mESCs were exposed to LMOs encoding the mutations of interest. LMO-exposure introduced the 
mutation into the endogenous Msh6 gene in ±1 per 1000 Msh6+/- mESCs. (B) To determine if the subset of cells 
carrying the mutation in the Msh6+ allele had lost MMR activity, the mESCs were treated with 6TG. MMR-
proficient cells die in response to 6TG exposure while MMR-deficient cells are 6TG resistant. (C) Cells may also 
lose MMR capacity due to loss of heterozygosity (LOH) events deleting the Msh6+ allele. To exclude these cells 
from further investigation, a PCR was performed that detected the presence of both Msh6 alleles. (D) 6TG-
resistant LMO-exposed mESCs that maintained the Msh6+ allele were sequenced to confirm the presence of 
the planned mutation.  
 
 
Proof of principle 
To demonstrate the ability of the oligonucleotide-directed mutagenesis screen to 
distinguish pathogenic MSH6 mutations from polymorphisms, a proof of principle study 
was performed with MSH6 variants G1139S and L1087R that were previously proven to 
be pathogenic and not pathogenic, respectively (25), as well as all classified pathogenic 
and not pathogenic missense variants described in the International Society for 
Gastrointestinal Hereditary Tumours (InSiGHT) colon cancer variant database 
(http://insight-group.org/). This database uses available clinical, in vitro and in silico data 
to categorize DNA MMR gene sequence variants according to a five-tiered classification 
scheme as: class 5, Pathogenic; 4, Likely pathogenic; 3, Uncertain; 2, Likely not 
pathogenic; and 1, Not pathogenic.(26) Msh6+/- mESCs were first exposed to antisense 
oriented LMOs encoding the desired base-pair substitution. If subsequent 6TG selection 
did not reveal resistant colonies encoding the planned mutation, the screen was 
repeated with sense oriented LMOs.  
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LMO-mediated introduction of both pathogenic and not pathogenic variants led to the 
appearance of 6TG-resistant colonies. The vast majority of 6TG-resistant colonies 
obtained with LMOs encoding polymorphisms had lost the wild-type Msh6 allele by loss 
of heterozygosity events, as inferred from allele-specific PCR analysis. Sequencing of the 
few 6TG-resistant colonies that had retained both Msh6 alleles (±6%), did not detect any 
mutation (Figure 2A). These background colonies apparently arose from cells that for 
unknown reasons survived 6TG exposure. Of the 6TG-resistant colonies that emerged 
following LMO-mediated introduction of pathogenic mutations, ±40% still contained 
both Msh6 alleles. Sequence analysis detected pathogenic mutations in all but one of 
these 6TG-resistant colonies (Figure 2B; Figure S2A). Thus, the oligonucleotide-directed 
mutagenesis screen detected all 4 pathogenic mutations and not one of the 5 non-
pathogenic variants, indicating it is capable of distinguishing pathogenic MSH6 mutations 
from polymorphisms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Distinguishing pathogenic MSH6 variants from polymorphisms. 
 (A) Five known non-pathogenic variants and (B) four pathogenic mutations tested in the proof of principle 
study. Variants are annotated according to their amino acid change and location in men and mice. The 
nucleotide change was first introduced by antisense-oriented LMOs. If no 6TG-resistant colonies encoding the 
mutation appeared, the screening protocol was repeated with sense-oriented LMOs (lower row where two 
rows are present). The fourth column presents the InSiGHT classification of each variant where 5 is pathogenic, 
3 is uncertain and 1 is not pathogenic. At variance with the InSiGHT classification, a previous study 
demonstrated variant G1139S is pathogenic and L1087R is not pathogenic (25). The bars in the ‘Fraction of 
6TG-resistant colonies carrying mutation’ column represent the 18 6TG-resistant colonies that were 
investigated further. The white portions represent colonies in which the Msh6+ allele was lost by LOH; the light 
grey portions illustrate the fraction of background colonies that apparently survived 6TG selection but 
maintained the Msh6+ allele without the planned mutation; the dark grey portions represent the fractions of 
colonies that maintained the Msh6+ allele and encoded the mutation of interest.  
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Screening variants of uncertain significance 
We used the oligonucleotide-directed mutagenesis screen to investigate the phenotype 
of 18 MSH6 VUS described in literature and the InSiGHT database as well as 8 MSH6 VUS 
detected in suspected-LS patients from the Erasmus Medical Center Rotterdam and the 
Radboud University Medical Center Nijmegen (see Tables S1 and S2 for clinical data (27-
38); see Figure S3 for location of variants in MSH6 (39, 40)). Of the 26 variants, 18 were 
not present in 6TG-resistant colonies and hence do not appear to affect MMR activity. 
Mutations R510G, A586P, G683D, F703S, L1060R, E1191K, T1217D and T1217I were 
identified in 6TG-resistant colonies by sequence analysis (Figure 3A and B; Figure S2B). 
The MMR abrogating effect of all Msh6 variants conferring 6TG-resistance was further 
characterized by Western blot analyses, MSI assays and methylation-damage-induced 
mutagenesis assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Identification of pathogenic MSH6 VUS. 
The genetic screen was used to analyze (A) 18 VUS selected from literature and the InSiGHT database as well as 
(B) 8 VUS identified in patients from two medical centers in the Netherlands. Variants are displayed according 
to their amino acid number and change in men and mice. The ‘Nucleotide change’ column presents the one or 
two base alteration introduced by the LMOs. If antisense-oriented LMOs did not give rise to 6TG-resistant 
colonies encoding the mutation of interest, the screen was repeated with sense-oriented LMOs (lower row 
where two rows are present for the variant). The InSiGHT classification of each variant is indicated: 4, likely 
pathogenic; 3, uncertain; 2, likely not pathogenic; NA, not available. The bars in the ‘Fraction of 6TG-resistant 
colonies carrying mutation’ column represent the 18 6TG-resistant colonies that were analyzed for the 
presence of the planned mutation: the white segments represent LOH events; the light grey segments 
represent background colonies that maintained the Msh6+ allele but did not encode the planned mutation; the 
dark grey segments display the fractions of colonies that maintained the Msh6+ allele and encoded the 
mutations of interest. 
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Phenotypic assessment of identified MMR abrogating Msh6 variants 
The effect of the identified MMR abrogating mutations on MSH6 and MSH2 protein 
levels was evaluated by Western blot analyses (Figure 4). MSH6 and MSH2 form a 
heterodimer; consequently, a drop in MSH6 levels is often associated with a slight 
decrease in MSH2 protein stability. Protein levels were quantified with respect to 
Msh6+/- mESCs, which maintain a functional MMR system with about two-third of the 
MSH6 level observed in Msh6+/+ mESCs.(25) Known pathogenic mutations V397E, L448P, 
G1137S and R1332Q reduced MSH6 levels to 7-33% of that seen in Msh6+/- mESCs. The 
R1332Q mutation is located in the splice donor site of exon 9 which may explain the 
appearance of a shorter protein. The drop in MSH6 levels seen for the known pathogenic 
mutations was mirrored by variants A586P, G683D, F703S and L1060R that reduced 
protein levels to 7-24%. Variants R510G, E1191K, T1217D and T1217I maintained 
relatively high MSH6 levels of 59-79%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Western blot analysis of mESCs expressing Msh6 variants. 
MSH6, MSH2 and γ-TUBULIN levels were analyzed in whole cell lysates. MSH6 and MSH2 levels in the variant 
cells lines were quantified with respect to the protein levels seen in Msh6+/- mESCs. 
 
MSI in MSH6 mutation carriers is largely restricted to mononucleotide markers.(41) To 
investigate the effect of the detected Msh6 variants on MSI we used a (G)10-neo slippage 
reporter. The neomycin resistance gene (neo) in this reporter is rendered out of frame by 
a preceding (G)10 repeat. When DNA polymerase slippage errors at the (G)10 repeat such 
as the deletion of one G or insertion of two Gs remain unnoticed, the neo becomes in 
frame and generates Geneticin-resistant cells. Hence the number of Geneticin-resistant 
colonies is indicative of the frequency of neo-restoring slippage events and the MMR 
capacity of the cells.(42) The slippage rates, i.e., the chance of a slippage event occurring 
during one cell division, in 6TG-resisant Msh6 VUS expressing mESCs ranged from 5.3x10-
5 to 5.1x10-4; which is around the average rate of 1.9x10-4 observed for the known 
pathogenic mutations and 140 to 1340-fold higher than the slippage rate of 3.8x10-7 
seen for Msh6+/- MMR-proficient mESCs (Figure 5). 
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Figure 5. MSI analysis of mESCs expressing Msh6 variants. 
To quantify the level of MSI, a (G)10-neo slippage reporter was introduced into variant mESCs. Spontaneous 
DNA polymerase slippage events on the (G)10 repeat that are not corrected can bring the neo in frame, 
rendering cells Geneticin-resistant. Slippage rates (the emergence of a Geneticin-resistant cell per cell division) 
of VUS expressing cells are compared to the MMR-proficient Msh6+/- cell line and MMR-deficient Msh6 V397E/-, 
Msh6 L448P/-, Msh6 G1137S/-, and Msh6 R1332Q/- pathogenic controls. Statistical differences were calculated using one-
tailed, unpaired t-test with Welch’s correction. Asterisks indicate values significantly higher than those of the 
MMR-proficient Msh6+/- control: *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
 
 
In addition to increased spontaneous mutagenesis events, MMR-deficient cells also 
experience increased methylation-damage-induced mutagenesis .(43) To study the 
influence of the detected MMR attenuating Msh6 variants on methylation-damage-
induced mutagenesis, mESCs were exposed to the methylating DNA damaging agent N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG) and the number of cells that consequently 
attained mutations was quantified. In MMR-proficient cells, DNA replication across 
MNNG-induced O6-methylguanine lesions is impaired by futile cycles of MMR, ultimately 
leading to cell death and suppression of methylation-damage-induced mutagenesis. 
Under MMR-deficient conditions, however, the MNNG-induced mismatches are not 
recognized and remain in the genome leading to the accumulation of mutations. To 
provide a quick read out for the frequency of mutation accumulation, we measured the 
number of MNNG-exposed cells that became resistant to a high dose of 6TG for an 
extended period. Solely cells that carry an inactivating mutation in Hprt survive stringent 
6TG treatment because HPRT is required for 6TG to behave as a DNA damaging agent. All 
detected Msh6 variant cell lines showed an elevated MNNG-induced mutator phenotype 
when compared to the MMR-proficient Msh6+/- mESCs (Figure 6).  
 
Phenotypic assessment of a non-detected Msh6 variant 
According to literature MSH6-G566R may be pathogenic (33, 44), yet our screen did not 
identify this variant in 6TG-resistant colonies. Hence we investigated whether the MMR 
abrogating effect of Msh6-G565R could have been missed by the screen due to technical 
difficulties. Rather than applying 6TG selection after oligonucleotide-directed 
mutagenesis, we purified Msh6G565R/- mESCs using a Q-PCR-based protocol (Figure S2C) 
(25) and subsequently examined their MMR capacity. Exposure of Msh6G565R/- cells to 
increasing doses of 6TG revealed that they were equally sensitive to 6TG as Msh6+/- cells 
(Figure 7A). In the MSI assay, Msh6G565R/- mESCs did not experience significantly more 
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slippage events than the MMR-proficient control (Figure 7B). Thus, Msh6-G565R did not 
attenuate MMR consistent with the oligonucleotide-directed mutagenesis screening 
result.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. MNNG-induced mutagenesis in mESCs expressing Msh6 variants. 
Variant MSH6 expressing mESCs were exposed to MNNG and the number of cells that consequently acquired 
mutations in Hprt quantified (29). Hprt-defective mESCs were identified by long-term exposure to a high dose 
of 6TG (10 μg/ml). The spontaneous (-) and MNNG induced (+) mutation frequency was compared to MMR-
proficient Msh6+/- mESCs and MMR-deficient Msh6 V397E/-, Msh6 L448P/-, Msh6 G1137S/-, and Msh6 R1332Q/- pathogenic 
controls. The statistical differences between MNNG-treated Msh6+/- mESCs and MNNG-treated variant cell lines 
was calculated using a one-tailed, unpaired t-test with Welch’s correction. Asterisks indicate values significantly 
higher than those of the MNNG-treated MMR-proficient Msh6+/- control: *P<0.05; **P<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. MMR capacity of Msh6G565R/- mESCs. 
The MMR activity of Msh6G565R/- mESCs was investigated using two assays. (A) 6TG survival assay. The colony-
forming capacity of Msh6G565R/- mESCs as well as MMR-deficient Msh6-/- and MMR-proficient Msh6+/- and 
Msh6+/+ cells was determined in response to increasing doses of 6TG. (B) MSI in the Msh6G565R/- mESCs was 
investigated using the (G)10-neo slippage reporter. The slippage rate (the emergence of a Geneticin-resistant 
cell per cell division) in Msh6G565R/- cells was compared to the rate in MMR-proficient Msh6+/- and MMR-
deficient Msh6V397E/- control cell lines. Statistical differences were calculated using one tailed, unpaired t-test 
with Welch’s correction. **** indicates significantly higher than the mismatch repair proficient Msh6+/- control: 
P<0.0001. 
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DISCUSSION 
 
The results of our study demonstrate the oligonucleotide-directed mutagenesis screen 
we previously described for the characterization of MSH2 VUS (22) can be extended to 
MSH6 VUS. Combining oligo targeting in Msh6+/- mESCs with 6TG selection and sequence 
analysis allows pathogenic MSH6 variants to be distinguished from polymorphisms. The 
efficacy of the genetic screen was established in a proof of principle study with 4 known 
pathogenic MSH6 mutations and 5 polymorphisms. This number was low because of the 
paucity of MSH6 variants that were classified with 100% certainty. Not one of the 5 non-
pathogenic variants was identified as MMR abrogating. Also, among the 26 MSH6 VUS 
we subsequently analyzed, not one of the 4 variants classified as likely not pathogenic 
was identified as pathogenic by our screen. Finally, functional assays established that 
one of the VUS that was not detected as pathogenic by the screen indeed did not 
influence MMR activity (G565R). Hence the false positive rate of the screen, i.e., the 
chance the screen identified a VUS as MMR abrogating while it was a priori or a 
posteriori identified as (likely) non-pathogenic was <1/10, giving a specificity >90.0%. The 
sensitivity of the genetic screen is a measure of the false negative rate; it is the likelihood 
that a pathogenic mutation is not detected. All 6 InSiGHT classified pathogenic and likely 
pathogenic variants as well as the previously proven pathogenic G1139S mutation were 
recognized as MMR abrogating by the screen, translating to a sensitivity of >85.7%. 
 
We used the oligonucleotide-directed mutagenesis screen to investigate the MMR 
capacity of 26 MSH6 VUS. Eight of these were found in suspected-LS patients from two 
medical centers in the Netherlands. From this clinical cohort, the mouse equivalent of 
mutations R511G, A587P and F706S were detected by our screen and shown to abrogate 
MMR. However, R510G and F703S were detected in only 2/5 and 2/4 6TG-resistant 
colonies, respectively, that had retained two Msh6 alleles, while the other pathogenic 
variants were present in virtually all colonies diploid for MSH6 (Figures 2B, 3A and 3B). 
The poorer recovery of R510G and F7103S mutants may have been due to a lower 
success rate of LMO-mediated base-pair substitution. The pathogenic phenotype 
observed for these three variants is in line with clinical data: all three variants were 
detected in patients with MSI-H LS-related tumors and with a family history of LS-related 
tumors. In the case of VUS A587P and F706S, relatives with LS-related tumors carried the 
same mutation. IHC also demonstrated MSH6 was absent in the patients encoding 
MSH6-A587P and MSH6-F706S; the IHC data for MSH6-R511G were inconclusive. 
 
The other 5 variants in the clinical cohort, A25S, E221D, G670R, R922Q and c.3438+6T>C, 
were not identified as MMR abrogating. VUS E221D, G670R and R922Q were found in 
patients who also harbored a second, known pathogenic mutation in one of the DNA 
MMR genes that was likely causative for the LS phenotype. E221D was also detected in a 
second patient who was 83 years old and did not have a family history suspicious for LS. 
MSH6-A25S was found in a typical LS tumor, i.e., a colon tumor showing MSI, loss of 
heterozygosity of MSH6, and loss of MSH6 protein expression. The patient however only 
had one relative with a colorectal tumor and this tumor was not MSI-high and stained 
Chapter 8 
128 
positive for all MMR proteins. A previous in vitro study also suggested MSH6-A25S is not 
pathogenic (45); it could be that the tumor arose due to a missed somatic mutation. VUS 
c.3438+6T>C was found in a patient with a family history suspicious of LS. We however 
do not know if the relatives with LS-associated cancers also carried this specific MSH6 
sequence variant. IHC failed in the index patient carrying the c.3438+6T>C variant, 
therefore we cannot exclude that a somatic mutation or MLH1 hypermethylation caused 
the MSI in the tumor. Tumor tissue of one family member was tested and showed no 
MSI and normal IHC. It is also possible that the genetic screen was unable to identify 
c.3438+6T>C as pathogenic due to differences between the human and mouse MSH6 
sequences. While the MSH6 coding sequence is highly conserved, intron sequences are 
more variable between species (Figure S4 shows human and mouse sequence around 
c.3438+6). Hence there is a chance that variant c.3438+6T>C affects splicing in man but 
not in mice. According to several splice site prediction programs (NNSPLICE, GeneSplicer, 
Human Splicing Finder), however, c.3438+6T>C does not affect splicing.  
 
The other 18 MSH6 VUS we studied were attained from literature and the InSiGHT 
database. The genetic screen found 5 of these variants abrogate MMR: G686D, L1063R, 
E1193K, T1219D and T1219I. The detection of G686D and L1063R is in line with their 
InSiGHT classification, which describes the mutations as likely pathogenic. Variant 
E1193K has previously been suggested to cause LS in studies that identified the mutation 
in patients with ECs that were MSI and did not stain for MSH6.(27, 31) Not much clinical 
data is available for VUS T1219D but Msh6T1217D mice were demonstrated to have 
increased cancer susceptibility.(46) VUS T1219I has been described in a CRC patient who 
had a family history of CRC and a MSI tumor that stained positive for MSH6, the latter 
being consistent with the high levels of this variant protein we observed in mESCs. Both 
clinical and in vitro data indicate MSH6-T1219I abrogates MMR activity.(29, 45) 
 
MSH6 VUS R128L, R468H, V509A, Y556F, P623A, S666P, E983Q, R1095C, T1255M and 
R1304K were not identified as pathogenic in our screen. These sequence variants were 
classified as likely not pathogenic by InSiGHT, identified in patients with MLH1 promoter 
methylation or with MSS and MSH6 positive tumors, or observed in patients for whom 
little clinical data was available. VUS S285I, G565R and T1142M were also not detected 
as MMR attenuating by our screen, yet they seem suspicious for pathogenicity based on 
available data. MSH6-T1142M was previously suggested to be probably pathogenic 
based on clinical data describing the variant in a 27 year old patient with polyps who met 
the Bethesda guidelines, had a 61 year old mother with polyps, and did not carry 
pathogenic mutations in any other MMR gene nor showed MLH1 promoter methylation 
in the tumor.(35) VUS S285I and G566R were detected in CRC patients with MSI (low and 
high, respectively) tumors that had loss of heterozygosity of MSH6.(33) Cyr and Heinen 
(44) investigated the effect of these two mutations on mismatch binding and processing: 
variant S285I was not found to have a specific MMR attenuating effect but variant G566R 
was suggested to abrogate MMR by interfering with the ATP-dependent conformational 
change that must take place to activate downstream repair pathways upon mismatch 
binding. We therefore purified Msh6G565R/- mESCs and assessed their MMR capacity. The 
Msh6G565R/- cells behaved like MMR-proficient Msh6+/- mESCs, confirming the result of 
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the oligonucleotide-directed mutagenesis screen. Despite the good performance of our 
screen and the high amino acid conservation of MSH6, we cannot exclude Msh6-G565R 
was not identified as pathogenic due to differences between mice and men. To fully 
dissuade this argument we will need to develop the oligonucleotide-directed 
mutagenesis screen in human cells.  
 
The oligonucleotide-directed mutagenesis screen presented here is a relatively simple 
tool that can be used to investigate the pathogenic phenotype of many MSH6 VUS in 
parallel. While the evolutionary conservation of MMR justifies the use of mouse cells for 
the majority of VUS, testing of splice-site and intronic mutations necessitates adaptation 
to human cells. Also, as long as uncertainty exists about its specificity and sensitivity, 
functional testing needs to be combined with clinical data and in silico estimations to 
arrive at a reliable classification of VUS. Conforming the updated American College of 
Medical Genetics and Genomics (ACMG) standards and guidelines for sequence variant 
interpretation, we are currently transferring our functional tests to certified Clinical 
Genetics laboratories and creating an infrastructure where test results are compared and 
interpreted taking into account all available data. In this way, LS mutation carriers can be 
identified with the highest certainty and enrolled in tailored surveillance programs while 
relatives without the mutation can be excluded from surveillance. 
 
 
METHODS 
 
Oligonucleotide-directed mutagenesis screen to identify pathogenic MSH6 variants 
The genetic screen was developed in Msh6+/- mESCs, which contain one active Msh6 
allele (Msh6+) and one Msh6 allele that was disrupted by the insertion of a puromycin 
resistance marker (Msh6-).(24) The MSH6 variants under investigation were introduced 
into the Msh6+/- mESCs by oligo targeting using LMOs.(23) 7x105 Msh6+/- mESCs were 
seeded in BRL-conditioned medium on gelatin-coated 6 wells and exposed to a mixture 
of 7.5 μl TransIT-siQuest® transfection agent (Mirus), 3 μg LMOs and 250 μl serum-free 
medium the following day. After 3 days, 1.5x106 LMO-exposed cells were transferred to 
gelatin-coated 10 cm plates and subjected to 6TG (250 nM) (Sigma-Aldrich®) selection. 
After 10 days the 18 largest 6TG-resistant colonies were picked. Cells that became 6TG-
resistant due to loss of heterozygosity events were excluded from further analyses using 
a PCR specialized to detect the presence of both the disrupted and non-disrupted Msh6 
alleles.(24) 6TG-resistant mESCs that maintained both Msh6 alleles were sequenced to 
confirm the presence of the planned mutation. 
 
Western blot analysis 
Western blot analyses were performed as described in Wielders et al.(25) Rabbit 
polyclonal antibodies against mMSH2 (1:500) (47) and mMSH6 (1:500) (24) as well as 
mouse polyclonal antibody against γ-Tubulin (1:1000; GTU-88 Sigma-Aldrich®) were used 
as primary antibodies. Protein bands were visualized using IRDye® 800CW goat anti-
rabbit IgG and IRDye 800CW® goat anti-mouse IgG secondary antibodies (Li-cor) and the 
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Odyssey scan. The infrared fluorescent signals measured by the Odyssey scan are directly 
proportional to the amount of antigen on the Western blots, allowing quantification of 
the protein bands. 
 
Microsatellite instability assay 
mESCs were electroporated with the (G)10-neo Rosa26 targeting vector as described in 
Dekker et al.(48) The (G)10-neo Rosa26 targeting vector is composed of a promoterless 
histidinol resistance gene as well as a neomycin resistance gene (neo) that is rendered 
out of frame by a preceding (G)10-repeat.(42) Once electroporated, 10
6 cells were seeded 
on gelatin-coated 10 cm plates in BRL-conditioned medium and exposed to Histidinol 
(3mM) (Sigma-Aldrich®). Successful integration of the vector into the Rosa26 locus of the 
Histidinol-resistant colonies routinely occurs at a frequency of ±95% and was confirmed 
by Southern blot analyses. The individual successfully targeted colonies were 
subsequently expanded to 107 cells and transferred to gelatin-coated 10 cm plates at a 
density of 105 cells per plate for Geneticin selection (600 μg/ml) (Life Technologies). 
After 10 days, the number of Geneticin-resistant colonies was counted and the slippage 
rate of the variant mESCs calculated using the formula: 0.6 x Geneticintotal = N x p x log (N 
x p), where Geneticintotal is the number of Geneticin-resistant colonies, N the number of 
cells to which the culture was expanded, and p the number of mutations per cell division. 
Experiments were performed in quadruplicate and statistical differences calculated using 
a one-tailed, unpaired t-test with Welch’s correction.  
 
MNNG-induced mutagenesis assay 
The MNNG-induced mutagenesis assay was performed as described in Claij and te 
Riele.(43) 2.5x106 variant mESCs were seeded on an irradiated mouse embryonic 
fibroblasts feeder layer in 10 cm plates and exposed to 0 or 4μM MNNG (Sigma-Aldrich®) 
for 1h the following day. 40 μM O6-benzylguanine was present in the medium from 1h 
prior to the MNNG treatment until 6 days after, at which point 1.5x106 cells were 
transferred to gelatin-coated 160 cm2 plates for 6TG selection (10 μg/ml). After two 
weeks of 6TG selection, the number of resistant colonies and hence the frequency of 
MNNG-induced Hprt mutants could be determined. Experiments were performed in 
duplo and the statistical difference between MNNG-treated Msh6+/- mESCs and MNNG-
treated variant cell lines calculated using a one-tailed, unpaired t-test with Welch’s 
correction. 
 
Generation of Msh6G565R/- mESCs 
Msh6G565R/- mESCs were made as described by Wielders et al.(25) Variant G565R was 
introduced into Msh6+/- mESCs by oligo targeting and a pure Msh6G565R/- mESC clone was 
obtained by consecutive rounds of seeding and mutation specific PCR: oligonucleotide-
exposed cells were expanded and subsequently seeded on a 96-well plate at a density of 
5000 cells per well. A mutation-specific quantitative PCR was used to identify wells that 
contained Msh6G565R/- mESCs. Positive wells were reseeded at lower density and positive 
wells again identified by Q-PCR. A pure clone was finally obtained by seeding single cells 
per well. Sequence analysis confirmed the creation of Msh6G565R/- mESCs. 
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6TG DNA damage response assay 
The 6TG sensitivity of Msh6G565R/- mESCs was investigated by exposing the variant cell 
line to increasing doses of 6TG, as described in Wielders et al.(49) MMR-deficient Msh6-/- 
and MMR-proficient Msh6+/- and Msh6+/+ mESCs were taken along for comparison.  
 
Clinical data 
We investigated the pathogenic phenotype of MSH6 VUS that were found in suspected-
LS patients at the Clinical Genetics departments of the Erasmus Medical Center 
Rotterdam and Radboud University Medical Center Nijmegen. We collected tumor 
characteristics, age at diagnosis, results of molecular diagnostics and germline mutation 
analysis, and family history from medical records. MSI analysis was performed with the 
Bethesda panel (50) or with the Promega pentaplex MSI analysis.(51) IHC for MLH1, 
MSH2, MSH6 and PMS2 protein was performed as described previously.(52) Germline 
mutation analysis of MSH6 was performed by sequencing and multiplex ligation 
dependent probe amplification. The in silico prediction model PolyPhen (53) was used to 
estimate the chance of a variant being deleterious. 
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SUPPLEMENTAL MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Alignment of human and mouse MSH6 amino acid sequences demonstrating conservation of studied 
variants. 
Asterisks mark amino acids that are not conserved between the human (upper row) and mouse (lower row) 
MSH6 proteins. The positions of the studied MSH6 variants are highlighted: known pathogenic variants in red, 
known not-pathogenic variants in green, detected 6TG-resistant variants in mustard, non-detected variants in 
blue. 
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Figure S2. Sequences of Msh6 variants detected by genetic screen and Msh6G565R/- mESCs. 
Msh6 sequences in mESCs expressing (A) pathogenic variants in proof of principle study, (B) VUS detected in 
6TG-resistant colonies, and (C) variant Msh6-G565R. Note that in most cases the sequences are a superposition 
of the variant allele and the normal sequence of the Msh6- allele. One-letter amino acid codes are annotated 
below the nucleotide sequences. Msh6 WT is the wild-type Msh6 sequence. 
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Figure S3. Location of the studied mutations in the MSH6 protein. 
The MSH6 domains are displayed in different colors (1, 2). The studied mutations are annotated according to 
their amino acid number and change. The detected variants are depicted above the MSH6 domains: in orange 
are the 4 mutations in the proof of principle study, in purple are the 6TG-resistant VUS. Undetected variants 
are displayed below the MSH6 domains: in green are the non-pathogenic variants in the proof of principle 
study, in blue are the VUS that did not give rise to 6TG-resistance.  
1. Warren JJ, et al. (2007) Structure of the human MutSα DNA lesion recognition complex. Cell 26:579-92. 
2. Terui H, Akagi K, Kawame H, Yura, K (2013) CoDP: predicting the impact of unclassified genetic variants in 
MSH6 by the combination of different properties of the protein. J Biomed Sci 20:25. 
 
 
 
 
 
 
 
 
Figure S4. Alignment of human and mouse sequences around human MSH6 c.3438+6T. 
Depicted are the exon and intron sequences around position c.3438+6 in human MSH6 (upper) as well as the 
corresponding mouse sequence (lower). The amino acid codons are marked in blue and green and the 
corresponding amino acids are indicated above and below the sequences. hMSH6 c.3438+6T and mMSH6 
c.3432+6T are highlighted in red. 
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Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) 
predisposition and accounts for 2-3% of all CRC cases. Individuals with LS are also at 
increased risk of developing extracolonic cancers, especially endometrial cancer in 
women. LS is caused by autosomal dominant mutations in the mismatch repair genes 
MLH1, MSH2, MSH6 or PMS2, or by deletions of the 3’region of the EPCAM gene. Since 
surveillance programs can significantly reduce cancer morbidity and mortality in LS 
patients, the identification of these individuals is of great importance. 
 
 
IDENTIFICATION OF LYNCH SYNDROME PATIENTS 
 
Prediction models 
Several prediction models that can calculate the probability that an individual has LS are 
available. The prediction models MMRpro, MMRpredict and PREMM5 are available 
online free of charge.(1-3) Despite the easy web-based access, MMRpro is less useful in 
clinical practice since extensive information on all family members is needed, such as 
current age of every healthy relative. All three models have been shown to perform well 
for the identification of LS patients.(4-10) However, in many studies germline mutation 
analysis was not performed for all patients and therefore LS patients may have been 
missed. Especially in MSH6 and PMS2 mutation carriers, family history is less informative 
due to the lower cancer risk compared to MLH1 and MSH2 mutation carriers. 
 
In fact, chapter 3 shows that while the prediction models MMRpredict and PREMM5 can 
adequately predict whether an individual is likely to have Lynch syndrome caused by 
mutations in MLH1, MSH2 and MSH6, they fail to identify PMS2 mutation carriers. To 
improve the performance of the PREMM5 model, we added the location of the CRC to 
the model, as it is known that CRC in LS patients more often develops proximal from the 
splenic flexure than CRC in the general population. This addition to the PREMM5 model 
improved the overall performance as well as the identification of PMS2 mutation 
carriers. These results were also confirmed in a validation cohort. The MMRpredict 
model already includes the side of CRC as a variable in the model and therefore could 
not be improved further. Interestingly, MMRpredict can only be used for CRC patients, 
whereas PREMM5 can also calculate the probability of a healthy individual to have LS 
and could therefore be used in different clinical settings. 
 
The US Multi-Society Task Force on Colorectal Cancer recommends germline mutation 
analysis in individuals with a risk of carrying a MMR gene mutation ≥5% according to one 
of the prediction models MMRpro, MMRpredict or PREMM.(11) The authors who 
developed the PREMM5 model suggest a cut-off of 2,5% in order to identify PMS2 
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mutation carriers.(3) Strategies including prediction models to identify LS patients might 
lower the cost of screening for LS. Cost-effectiveness analyses found that strategies 
including prediction models and/or family-history assessment were more cost-effective 
than those involving direct tumor testing of all CRC patients, if these prediction models 
were perfectly implemented.(12, 13) However, family data is not always reliable or 
available and in practice, even the more compact revised Bethesda guidelines were 
shown to be underutilized.(14, 15) Routine screening of CRC patients by molecular 
diagnostics seems much more likely to be well implemented than the revised Bethesda 
guidelines or prediction models in clinical practice. In fact, in a cost-effectiveness study 
underutilization of the revised Bethesda guidelines made routine LS screening by 
molecular diagnostics the preferred strategy.(13) Another use for prediction models 
could be to select patients from population based screening programs in whom 
screening for LS could be performed. In a meta-analysis, prediction models indeed 
performed better in population-based cohorts than in clinic-based cohorts.(10) Also, in 
cases where no tumor tissue is available or where tumor tissue analysis failed, prediction 
models could help assess whether an individual should be analyzed for a germline MMR 
mutation. In high risk populations however, such as patients referred to a clinical 
geneticist, prediction models will likely be less useful. In such a selected patient group, 
molecular diagnostics for LS as a first step has relatively low costs, a priori chance of 
finding a MMR mutation is assumed to be high depending on the guidelines for referral 
and off course specificity of prediction models is not 100%. Furthermore a clinical 
geneticist will always draw an extensive pedigree and not only weighs the number of 
family members who developed cancer and the ages of onset of different types of 
cancer, but also takes into account if there are many relatives who have not developed 
cancer or if the family is very small with a relatively high frequency of cancer. Since 
family size has decreased over the last decades prediction models may increasingly lead 
to lower predictions in LS patients. In settings with a very low capacity of molecular 
testing and/or germline mutation analysis, prediction models may play a larger role in 
order to optimize the use of the available resources. 
 
Routine molecular screening for Lynch syndrome 
Colorectal cancer patients 
Analysis of microsatellite instability (MSI) and immunohistochemistry (IHC) on tumor 
tissue can be used as a screening tool to identify patients who are likely to have LS.(16) 
For a long time, routine screening for LS was performed for CRC patients <50 years of 
age, thereby missing mostly MSH6 and PMS2 mutation carriers. Chapter 4 shows routine 
screening for LS in CRC patients ≤70 years of age by analysis of MSI, IHC and MLH1 
hypermethylation is cost-effective according to currently accepted standards. Expanding 
the age limit for routine screening for LS among CRC patients from 50 to 60 years of age 
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remained <€10.000/LYG in sensitivity analysis. The incremental cost effectiveness ratio 
(ICER) for further expansion of the age limit from 60 to 70 years of age never exceeded 
€13.000/LYG. These ICERs are well within the currently accepted thresholds for cost-
effectiveness of €40.000/LYG in the Dutch healthcare system.(17) Several studies 
indicate that a screening strategy using only IHC instead of MSI analysis and IHC together 
may be even more cost-effective.(13, 18) 
 
In our study, the ICER for LS screening among CRC patients ≤70 years of age compared 
with testing according to the revised Bethesda guidelines remained <€13.000/LYG and 
therefore cost-effective in the Dutch setting. Furthermore, age-targeted LS screening will 
be much easier to use and by better implementation may be even more cost-effective in 
clinical practice than criteria based on family history. In most Western countries cost-
effectiveness threshold similar to the Dutch setting are used, and some authors advocate 
even higher thresholds.(17, 19) However, in low-income countries lower cost-
effectiveness thresholds might cause screening for LS not to be cost-effective.(20) 
 
International guidelines for screening for LS have indeed been extended in recent years, 
recommending screening for LS by analysis of MSI and/or IHC in CRC patients up to 70 
years.(11, 21) The American guidelines even recommend universal LS screening for CRC 
patients, without any age cut-off.(11) Of course, this will probably increase the number 
of LS patients identified. However, it is unclear whether this is also cost-effective, as the 
likelihood of underlying LS decreases with the increase of the age of CRC diagnosis. In 
chapter 4, LS was diagnosed in 4,9% of the CRC patients ≤50 years of age, 2,1% of the 
patients aged 51-60 years of age and 1,5% of the patients 61-70 years of age. Also, as 
most CRC patients are >70 years of age, there would be an enormous increase of 
patients screened for LS, with a low a priori risk of having LS. In one cost-effectiveness 
study universal LS screening in CRC patients was indeed not cost-effective.(12) However, 
as MSI analysis may also be increasingly performed in order to determine whether 5FU 
chemotherapy is beneficial, universal screening for LS may become part of routine 
diagnostics. It is important to secure the routing of the results of MSI and/or IHC analysis 
in clinical practice, in order to offer adequate counseling and germline mutation analysis 
in patients with aberrant results. Also, patients with CRC at a very young age or with a 
strong family history of CRC should still be referred to a clinical geneticist, even if the 
results of molecular diagnostics are not suspect for LS. For example, in these families, 
there might be a different CRC predisposition. 
 
Endometrial cancer patients 
Similar to LS screening in CRC patients, routine molecular screening is also recommended 
for endometrial cancer (EC) patients.(11, 21) While not many studies on the cost-
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effectiveness of LS screening among EC patients have been performed, all concluded that 
some form of LS screening among these patients was cost-effective.(22-24) In chapter 5, 
the ICER for routine screening for LS among EC patients up to 70 years of age compared 
to 50 years of age remained <€13.000/LYG. EC patients will likely benefit more from LS 
surveillance than CRC patients, since development of CRC can still be prevented in these 
patients and the mortality rate for LS patients diagnosed with CRC is higher than in LS 
patients diagnosed with EC.(25) Therefore, the cost-effectiveness of routine LS screening 
among EC patients may be even higher than for CRC patients. More research is needed in 
larger cohorts of EC patients to determine the cost-effectiveness of screening for LS in 
these patients with an age cut-off over 70 years, or even universal screening. In cohort 
studies of EC patients without an age cut-off, a prevalence of LS of at least 2,1-3,9% was 
found.(26-28) 
 
The cost-effectiveness of screening for LS among CRC and EC patients is mainly based on 
the identification of healthy relatives carrying the same MMR mutation, since these 
relatives will benefit the most from surveillance programs for LS. This stresses the 
importance of informing family members about the diagnosis and offering them genetic 
counseling and germline testing. In both our cost-effectiveness studies, a median of 3 
relatives were tested for each index patient. However, there was a very wide range from 
1-50 relatives that were tested per index patient. In the Netherlands, as in most 
countries, the index patient will inform relatives about the LS diagnosis. Most patients 
are satisfied with the current approach, where the diagnosis will be communicated by a 
family member.(29) During genetic counseling of an index patient, known risk factors for 
failure to communicate the diagnosis to relatives (such as disrupted family relations) 
should be evaluated in order to provide adequate assistance to communicate the 
diagnosis to family members. An important reason for relatives to refrain from germline 
mutation analysis in cancer predisposition syndromes is the possible effect on life 
insurance policies.(30, 31) It is important to inform relatives at risk of having LS about the 
possibility to enroll in LS surveillance programs if they refrain from germline mutation 
analysis. Also, education on symptoms of CRC and EC could be beneficial in these 
patients even if they opt not to participate in a surveillance program. 
 
Adenoma patients 
Molecular diagnostics for LS can also be performed in tissue other than CRC or EC. Little 
is known about the yield of LS screening for other types of cancer, such as bladder cancer 
or ovarian cancer. In two studies, a high percentage of 52% and 66% of the sebaceous 
neoplasms showed MMR deficiency.(32, 33) Unfortunately, germline mutation analysis 
was performed in only a small number of patients. Currently, no routine screening is 
recommended for other types of LS-associated cancer. 
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Loss of MMR expression is found in 50-84% of the adenomas from LS patients.(34-37) 
Screening for LS among patients with these precancerous lesions could provide an 
opportunity to identify LS index patients in whom development of cancer can be 
prevented. Chapter 6 shows that screening for LS in advanced adenomas found in a the 
national FIT-based CRC screening program is probably not effective. Screening among a 
subset of adenoma patients such as younger adenoma patients, however, might still be 
effective. In a previous study 3/125 (2,4%) advanced adenoma patients under 45 years of 
age were diagnosed with LS.(38) In LS patients, adenomas with a villous component or 
high grade dysplasia are most likely to show MSI and loss of MMR protein 
expression.(34-37) Therefore, screening only adenomas with a villous component or high 
grade dysplasia might be effective. In one study 5,4% of the adenomas (10/187) with 
high grade dysplasia showed aberrant IHC. However, MLH1 hypermethylation analysis, 
germline mutation analysis and somatic mutation analysis were not performed, so it is 
unclear how many of these patients actually could be diagnosed with LS.(39) Further 
research should focus on screening for LS by IHC analysis in adenomas from younger 
populations and/or with a villous component and high grade dysplasia. 
 
In clinical practice, molecular diagnostics for LS in adenoma tissue will be performed in 
selected cases, for example in families where there is no tumor available for testing. In 
recent years, at least two families have been diagnosed with LS in our center after IHC 
analysis on adenoma tissue. The first index patient was a man with a large tubulovilleus 
adenoma with high grade dysplasia at age 27 in whom a germline MSH6 mutation was 
found. In the second family a tubulovilleus adenoma was analyzed from a 34-year old 
woman, since CRC tissue from her sister (with CRC at age 22) was not available. A 
germline MSH2 mutation was identified in this patient. 
 
MMR deficiency is found in 12-20% of all CRC.(40-43) The MMR deficiency can be caused 
by an underlying germline MMR mutation, but can also be seen in some sporadic CRC. In 
these CRC, MMR deficiency is caused by hypermethylation of the MLH1 promoter or two 
somatic hits.(16, 44, 45) There is no data on the percentage of MMR deficiency among 
sporadic adenomas. Based on the results of chapter 6 with none of the adenomas 
showing MLH1 hypermethylation and only one adenoma in which two somatic 
mutations were found, MMR deficiency seems uncommon and not an early event in the 
adenoma-carcinoma sequence in the general population. 
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VARIANTS OF UNKNOWN SIGNIFICANCE 
 
In individuals suspected of having LS based on family history or the results of molecular 
diagnostics, germline mutation analysis is performed to confirm the diagnosis. In some 
patients, a variant of unknown significance (VUS) is found. The inability to determine the 
pathogenicity of such a DNA variant causes uncertainty for the index patients as well as 
their relatives. If a pathogenic variant is classified as a VUS, presymptomatic testing is 
not offered to family members. Moreover, relatives will be less likely to comply with 
surveillance recommendations until the diagnosis of LS is confirmed despite their risk of 
developing cancer.(46) In contrast, family members not at an increased risk of 
developing CRC may also undergo invasive surveillance procedures that they do not 
need. 
 
Co-segregation analysis of the VUS with MMR deficient tumors in family members and in 
silico prediction models are used for the classification of VUS. However, co-segregation is 
not always possible, especially in smaller families. With the decrease in family size co-
segregation will be less informative. Functional assays have been developed to 
determine the pathogenicity of VUS in the MMR genes.(47-50) 
 
With the expanding screening for LS , germline mutation analysis of the MMR genes will 
increasingly be performed. This will not only increase the number of LS patients being 
diagnosed, but will probably lead to more patients in whom a VUS in one of the MMR 
genes is found. Also, with the widespread use of whole exome sequencing, a germline 
VUS in one of the MMR genes can be an incidental finding. Therefore, the need for 
functional assays to distinguish pathogenic MMR gene variants from polymorphisms will 
increase. Once a VUS has been classified as either pathogenic or non-pathogenic, this 
classification can also be used for other patients carrying the same variant. 
 
The MMR genes are responsible for the repair of mismatches arising during DNA 
replication and can induce cell death in response to cytotoxic agents.(51, 52) In 2016, a 
functional assay for MMR gene variants was developed which starts with oligo targeting 
in embryonic stem cells from mice to insert a variant of interest in the MLH1 or MSH2 
gene.(49) These cells are subsequently treated with 6TG, which has a cytotoxic effect by 
inducing double-strand DNA breaks. If the MMR system in the cells functions properly, 
apoptosis will be induced as a result of the cytotoxicity of 6TG. In case of a pathogenic 
MMR mutation, however, cells can become resistant to DNA-methylating agents and cell 
death will not be induced. Hence, survival of cultures after 6TG treatment implies 
pathogenicity of the inserted variant. After identification of cultures resistant for 6TG, 
DNA sequencing is performed to confirm the presence of the VUS of interest in the cells 
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and to exclude MMR deficiency due to a somatic second hit in the cells. Chapter 7 
concerns the evaluation of 18 VUS in MLH1 and MSH2 that were identified in 21 
different families, using this functional assay. Seven MLH1 VUS and five MSH2 VUS were 
pathogenic according to the 6TG resistance in the cells. Western blot analysis showed 
that these cells had significantly lower protein levels for the corresponding MMR gene. 
All six other VUS were likely not pathogenic, which in four cases was in line with the (lack 
of) family history of LS-associated tumors in these patients and results of MSI and IHC 
analysis. In one patient, loss of MLH1 and PMS2 protein expression in the tumor is likely 
caused by the known pathogenic MLH1 mutation c.677+1delG that was found 
simultaneously with the VUS. The MLH1 VUS A31C was found in a patient with a tumor 
showing MSI without MLH1 hypermethylation. An additional evaluation of this VUS using 
CRISPR/Cas9 technology and MNNG-induced mutagenesis assays also showed MMR 
proficiency, which is in line with a previous report on the variant.(47) Off course, a 
variant could have a different effect on human cells than mice. Alternatively, a different 
mutation in MLH1 missed by DNA sequencing might be causing the phenotype in this 
patient, for example an intronic mutation. 
 
Non-pathogenicity of the MLH1 variants A31C, V213M and T549A and MSH2 variants 
N127S and N596S is in line with previous reports on these VUS.(47, 53-55) In silico 
predictions indicate that the MSH2 VUS R534C may be pathogenic.(56, 57) Although this 
VUS was identified in a patient with a MMR proficient tumor, he did develop two LS-
associated tumors and had a family history of cancer. Still, environmental factors and/or 
genetic factors other than the MMR genes could play a role in the development of 
cancer in this family. Other functional assays could be used to confirm the results of our 
assay. 
 
Chapter 8 shows that the genetic screen for MMR genes based on oligo targeting and 
selection for 6TG resistance, can also be used to determine pathogenicity of VUS in 
MSH6. Four known pathogenic variants were indeed resistant for 6TG treatment and five 
variants previously classified as non-pathogenic were also classified as non-pathogenic 
by the assay. After this proof of principle analysis, 26 VUS from clinical practice and from 
the International Society for Gastrointestinal Hereditary Tumours (INSIGHT) database 
were evaluated. Three out of the eight VUS found in clinical practice were indicated to 
be pathogenic, which was in line with the family history of LS-associated tumors in these 
patients and the presence of MMR deficiency in their tumors. Three other variants 
classified as non-pathogenic were found in patients in whom a simultaneously identified 
pathogenic MMR mutation was identified, explaining their phenotype. The last two VUS 
that were indicated to be non-pathogenic by the assay, were found in cases in whom no 
other cause of their MMR deficient tumors was identified. For one of these two VUS, 
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A25S, the classification as non-pathogenic was in line with a previous functional assay 
also indicating the variant not to be pathogenic.(48) The CRC in the patient carrying this 
VUS showed MSI, loss of MSH6 protein expression and loss of heterozygosity of MSH6. 
However, family history was not highly suspect for LS and a second somatic hit may have 
been missed in the tumor. In contrast, the second VUS that was classified as non-
pathogenic, c.3438+6T>C, was identified in a patient with a family history of LS-
associated tumors. However, IHC on tumor tissue failed and tumor analysis in a relative 
showed MMR proficiency. Unfortunately, segregation analysis could not be performed in 
this family. In this case, there could still be another explanation for the MMR deficient 
tumor in the index patient, such as somatic MMR mutations or MLH1 hypermethylation. 
However, especially since intron sequences are more variable between species, 
pathogenicity of the c.3438+6T>C variant cannot be excluded with absolute certainty, 
due to differences in the mouse and human DNA sequences. There could be a splicing 
effect from this variant in humans, which is not present in mice, although several splice 
site prediction programs do not predict aberrant splicing by c.3438+6T>C. 
 
The correct classification of a VUS in the MMR genes is highly important, because of the 
implications it has for eligibility for cancer surveillance. In order to obtain the most 
reliable classification, results of functional assays should be used in combination with 
other methods for the classification of VUS. These methods include clinical data such as 
cancer history, molecular diagnostics on tumor tissue of the index patient as well as 
relatives, and co-segregation analysis, and also the use of in silico prediction programs. 
Also, different functional assays could be used complimentary in cases with uncertain 
results, to achieve a high level of evidence for the classification of VUS and proper 
enrollment of individuals at high risk of developing cancer in tailored surveillance 
programs. 
 
 
SURVEILLANCE IN LYNCH SYNDROME PATIENTS 
 
The goal of identifying LS patients is of course to inform them on their increased cancer 
risk and to decrease cancer morbidity and mortality in these patients by surveillance 
programs. Guidelines recommend CRC surveillance by colonoscopy every 1-2 years 
starting from age 25. Since colonoscopies are invasive and burdensome, patients should 
not undergo unnecessary procedures. Despite the differences in cancer risk between the 
different MMR gene mutation carriers, surveillance is the same for all LS patients 
regardless of which MMR gene is involved. The yield of LS colonoscopy surveillance for 
carriers of a mutation in MLH1, MSH2, MSH6 and PMS2 is assessed in chapter 9. In most 
sessions no adenomas or CRC were found and there were no significant differences in 
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the number of adenomas that were found between the groups. However, the risk of 
finding advanced neoplasia increased at a slower pace in MSH6 mutation carriers than in 
the other MMR gene mutation carriers groups. None of the 121 MSH6 or 20 PMS2 
mutation carriers in our study developed CRC during follow-up, in line with their lower 
penetrance. Considering this slower pace of progression to advanced neoplasia, the fact 
that no CRC was found in these patients during follow-up and considering the size of the 
groups included, the colonoscopy interval in MSH6 mutation carriers may be less 
stringent than for MLH1 and MSH2 mutation carriers. Expanding the colonoscopy 
interval in these patients could lower the colonoscopy burden and might thereby even 
increase the adherence to the surveillance program. The fact that 3/9 CRCs that were 
found during follow-up were diagnosed after a delay between colonoscopies, 
emphasizes the importance of adherence to these programs. However, three patients 
with a MLH1 or MSH2 mutation developed CRC despite timely colonoscopies. These 
interval cancers are likely due to an alternative pathway for CRC development in LS, with 
MMR deficiency arising in a colonic crypt and direct progression to CRC without the 
development of an adenoma.(58, 59) Since no precursor lesion can be identified for CRC 
developing through this pathway, prevention by colonoscopic surveillance may be 
difficult. Nevertheless, early detecting of these CRC would improve survival in LS 
patients. 
 
Due to the small number of PMS2 mutation carriers included, no clear conclusions could 
be drawn for this group. However, based on the lower cancer risk in PMS2 mutation 
carriers, less frequent surveillance will probably be sufficient in these patients. 
Moreover, in a recent study no survival differences were found between LS patients 
undergoing colonoscopy surveillance yearly, every two years or every three years. At 
least for MSH6 and PMS2 mutation carriers, a colonoscopy interval of three years could 
therefore be justified. The median age of CRC is also higher in MSH6 and PMS2 mutation 
carriers than in MLH1 and MSH2 mutation carriers. In our study only a small number of 
young patients were included and we were unable to determine whether surveillance in 
MSH6 and PMS2 mutation carriers could start at a later age. However, in a study among 
CRC patients with a PMS2 mutation, 8% were diagnosed <30 years of age.(60) Larger 
cohorts of young MMR mutation carriers should be analyzed prospectively in order to 
determine the proper age to commence surveillance for all MMR genes. Similar studies 
on the yield of LS surveillance for gynecological cancer are needed. Also, patients with 
EPCAM gene mutations should be included in evaluations on LS surveillance. While their 
risk of developing CRC is comparable to the risk in MSH2 mutation carriers, the risk of 
developing EC is lower, implying less intensive gynecologic surveillance in these 
patients.(61) 
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The MMR gene involved is probably not the only factor that determines genotype-
phenotype correlation in LS patients. For example, truncating PMS2 mutations were 
shown to cause a more severe phenotype than non-truncating mutations.(62) Also, 
studies identified possible modifiers in MLH1 mutation carriers.(63, 64) Increasing 
knowledge on all these factors that can influence the phenotype of a patient can in time 
lead to truly personalized surveillance programs. 
 
In three out of five patients who died during follow-up in our cohort, the cause of death 
was pancreatic cancer, which is a cancer type with a very high mortality rate. In literature 
an increased risk of developing pancreatic cancer in LS is described by some but not 
others.(65-67) As CRC can be prevented or detected early in LS patients, other tumor 
types may become of increasing importance for survival of LS patients.  
 
 
FUTURE DIRECTIVES 
 
The guidelines for the identification of LS patients have been improved over the years. 
Considering the low cost of IHC analysis and high benefit of diagnosing LS (in index 
patients but most of all in healthy relatives by cascade testing), further expansion of 
screening for LS may still be cost-effective. Future research could focus on the 
identification of LS patients in tissue types that are currently not screened for LS, such as 
routine screening in ovarian and bladder cancers, or sebaceous adenomas. Although 
screening for LS in older adenoma patients was not effective, screening for LS in young 
adenoma patients should still be evaluated given the potentially high benefit of such a 
screening strategy with the ability to prevent the development of cancer in index 
patients. Also, the implementation of the current guidelines should be monitored, since 
the revised Bethesda guidelines were not well-used. 
 
As VUS found in the MMR genes pose an important problem for index patients as well as 
their relatives, effort needs to be undertaken to properly classify these variants. Clinical 
data, results for molecular diagnostics on tumor tissue, co-segregation analysis, in silico 
prediction programs and functional assays should be part of the routing to classify these 
VUS. 
 
In order to achieve surveillance programs tailored to the gene involved or even more 
personalized surveillance, large datasets of LS patients undergoing surveillance are 
needed. International collaborations are key in order to reach the numbers needed for a 
proper evaluation of surveillance programs, which should be stimulated by funding 
programs. 
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A promising technique which may change the surveillance of LS patients altogether, is 
the liquid biopsy. Liquid biopsies, such as the analysis of circulating tumor cells or cell 
free DNA (cfDNA) and micro-RNA in blood show great potential for monitoring disease 
progression and response to treatment in cancer patients.(68-71) If early stage cancers 
or even adenomas can be reliably detected through a blood test, this would reduce the 
number of invasive colonoscopy procedures needed in LS patients. Also, extracolonic 
tumors for which currently no screening is possible, might be identified by surveillance 
using liquid biopsies. 
 
In conclusion, the identification of LS has improved with the expanded screening for LS 
among cancer patients, functional assays are available to test VUS in the MMR genes and 
evidence for tailored surveillance programs for LS is emerging. Future research should 
focus on further improvement of the identification of LS patients (also among patients 
who have not yet developed cancer), the classification of VUS in the MMR genes, 
development of tailored surveillance programs for LS based on genotype, and the 
potential use of liquid biopsies in these surveillance programs. 
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SUMMARY 
 
This thesis focusses on Lynch syndrome, the most common hereditary predisposition for 
colorectal cancer. Lynch syndrome accounts for 2-3% of all colorectal cancer cases. The 
syndrome is caused by autosomal dominant mutations in the mismatch repair genes 
MLH1, MSH2, MSH6 or PMS2, or by deletions of the 3’region of the EPCAM gene. 
Individuals with Lynch syndrome not only have an increased risk of developing colorectal 
cancer, but also of developing extracolonic cancers, especially endometrial cancer in 
women. 
 
Chapter 1 consists of a general introduction on the subject, followed by the aims and 
outline of this thesis in chapter 2. 
 
Identification of Lynch syndrome patients 
Surveillance programs can significantly reduce morbidity and mortality in individuals with 
Lynch syndrome. However, in order to be offered surveillance, these individuals first 
have to be identified. Therefore, identification of individuals with Lynch syndrome is of 
great importance. 
 
Prediction models 
Several prediction models that can calculate the probability that an individual has Lynch 
syndrome are available. In chapter 3, two of these prediction models, MMRpredict and 
PREMM5, were evaluated in a cohort of 734 colorectal cancer patients. Both models 
could fairly predict whether an individual is likely to have Lynch syndrome, but PREMM5 
failed to identify Lynch syndrome patients with a PMS2 mutation, with an AUC of 0.52. 
We extended the PREMM5 model with the location of colorectal cancer as a new 
variable, which improved the identification of PMS2 mutation carriers (AUC 0.77) as well 
as its overall performance (0.81 vs. 0.72). These results were also confirmed in a 
validation cohort of 376 colorectal cancer patients. The extended PREMM5 model could 
for example be used to identify individuals eligible for Lynch syndrome diagnostics in 
populations with a low a priori risk of having Lynch syndrome, such as a population-
based screening program for colorectal cancer. 
 
Routine molecular screening for Lynch syndrome 
Tumors from Lynch syndrome patients show microsatellite instability and loss of 
mismatch repair protein expression at immunohistochemistry. Therefore, analysis of 
microsatellite instability and immunohistochemistry on tumor tissue can be used as a 
screening tool to identify patients likely to have Lynch syndrome. 
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Previous guidelines recommended molecular screening for Lynch syndrome in all 
colorectal cancer patients up to 50 years of age. In chapter 4 and 5 we assessed the cost-
effectiveness of routine molecular screening for Lynch syndrome in colorectal cancer 
patients and endometrial cancer patients up to 70 years of age. The incremental cost 
effectiveness ratio for expanding the age limit for routine Lynch syndrome screening 
among these patients from 50 to 70 years of age remained <€13.000 per life year gained 
in sensitivity analysis. This is well within the thresholds for cost-effectiveness (<€40.000 
per life year gained). Current international guidelines now recommend routine screening 
for Lynch syndrome by analysis of microsatellite instability and/or immuno-
histochemistry in patients with colorectal cancer or endometrial cancer up to at least 70 
years of age. 
 
The individuals benefiting the most from Lynch syndrome screening among colorectal 
and endometrial cancer patients, are healthy relatives of the index patients carrying the 
same mutation, since cancer can still be prevented in these individuals. Identification of 
Lynch syndrome patients among patients with adenomas (a precursor lesion of 
colorectal cancer) would ensure a similarly high benefit for the index patients. However, 
in chapter 6, no Lynch syndrome patients were identified by screening for Lynch 
syndrome among all advanced adenomas in the population based CRC screening 
program. Therefore, routine screening of all adenomas is probably not effective. 
Screening for Lynch syndrome among a subset of adenoma patients such as younger 
adenoma patients, however, might still be effective.  
 
Variants of unknown significance 
A definite diagnosis of Lynch syndrome is made when a pathogenic mutation in one of 
the mismatch repair genes MLH1, MSH2, MSH6 or PMS2, or a deletion of the 3’region of 
the EPCAM gene is found. In some cases, a variant of unknown significance is found and 
the diagnosis remains uncertain. The correct classification of a variant in the mismatch 
repair genes is highly important, because of the implications it has for eligibility for 
cancer surveillance.  
 
In chapter 7 and 8 a functional assay to classify variants of unknown significance in the 
mismatch repair genes is evaluated and 26 variants in MLH1, MSH2 and MSH6 are 
analyzed. Seven variants in MLH1, five variants in MSH2 and three variants in MSH6 were 
indicated to be pathogenic according to this functional assay. In most cases the 
classification was in line with clinical data, prediction programs and results of other 
functional assays. 
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Surveillance in Lynch syndrome patients 
The ultimate goal of identifying Lynch syndrome patients is to inform them on their 
increased cancer risk and to decrease their cancer morbidity and mortality by 
surveillance programs. Guidelines recommend colorectal cancer surveillance by 
colonoscopy every 1-2 years starting from age 25. Although the cancer risk in Lynch 
syndrome patients is highly dependent on the gene involved, all patients are currently 
offered the same surveillance. Therefore, chapter 9 evaluates the yield of colonoscopy 
surveillance in MLH1, MSH2, MSH6 and PMS2 mutation carriers. 
 
At most colonoscopies no adenomas or colorectal cancer were found and there were no 
significant differences in the number of adenomas that were found between the groups. 
However, the risk of finding advanced neoplasia (advanced adenoma or colorectal 
cancer) increased at a slower pace in MSH6 mutation carriers than in the other MMR 
gene mutation carriers groups. Considering this slower pace of progression to advanced 
neoplasia and the fact that none of the 121 MSH6 mutation carriers developed colorectal 
cancer during follow-up, the colonoscopy interval in MSH6 mutation carriers may be less 
stringent than for MLH1 and MSH2 mutation carriers. The interval between 
colonoscopies might be increased to three years for MSH6 mutation carriers. Due to the 
small number of PMS2 mutation carriers included, no clear conclusions could be drawn 
for this group. However, based on the lower cancer risk in PMS2 mutation carriers, less 
frequent surveillance will probably also be sufficient in these patients. 
 
Finally, chapter 10 discusses the results of this thesis in perspective of the current 
guidelines and clinical practice. 
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Dit proefschrift richt zich op Lynch syndroom, de meest voorkomende erfelijke aanleg 
voor darmkanker. Lynch syndroom is de oorzaak van 2-3% van alle darmkankers. Het 
syndroom wordt veroorzaakt door (autosomaal dominante) fouten in het DNA (mutaties) 
in de mismatch herstelgenen MLH1, MSH2, MSH6 of PMS2, of door het missen van een 
stuk DNA aan de achterkant van het EPCAM-gen. Mensen met Lynch syndroom hebben 
niet alleen een verhoogd risico op darmkanker, maar ook op het ontwikkelen van andere 
tumoren, met name baarmoederkanker bij vrouwen. 
 
Hoofdstuk 1 omvat een algemene introductie over het onderwerp, gevolgd door de 
doelstelling en opbouw van het proefschrift in hoofdstuk 2. 
 
Identificatie van Lynch syndroom patiënten 
Periodieke controles kunnen het ontstaan van darmkanker en de sterfte aan kanker bij 
Lynch syndroom patiënten fors verlagen. Echter, om deze controles aan te kunnen 
bieden, is het opsporen van mensen met Lynch syndroom van groot belang. 
 
Predictiemodellen 
Verschillende predictiemodellen die de kans kunnen berekenen dat een persoon Lynch 
syndroom heeft zijn beschikbaar. In hoofdstuk 3 werden twee van deze 
predictiemodellen, MMRpredict en PREMM5, geëvalueerd in een groep van 734 
patiënten met darmkanker. Beide modellen konden redelijk goed voorspellen of iemand 
Lynch syndroom heeft, maar PREMM5 kon Lynch syndroom patiënten met een PMS2 
mutatie niet goed identificeren. De voorspelling was slechts in 52% van de gevallen juist. 
We hebben het PREMM5 model uitgebreid met de locatie van de darmkanker als nieuwe 
variabele (rechts- of linkszijdig). Hiermee verbeterde zowel de identificatie van PMS2 
mutatiedragers (77% goed voorspellend) als de algehele prestatie van het model (van 
71% goed voorspellend naar 81% goed voorspellend). Deze resultaten werden bevestigd 
in een tweede (validatie) groep van 376 darmkanker patiënten. Het uitgebreide PREMM5 
model kan bijvoorbeeld worden gebruikt op mensen te identificeren die in aanmerking 
komen voor diagnostiek naar Lynch syndroom in populaties met een lage algemene kans 
op Lynch syndroom, zoals binnen het landelijke bevolkingsonderzoek naar darmkanker. 
 
Routinematige moleculaire screening voor Lynch syndroom 
Microsatellieten zijn repeterende stukjes in het DNA. Wanneer de mismatch 
herstelgenen niet goed functioneren, treden gemakkelijk fouten op in deze herhalingen, 
waardoor microsatellieten van verschillende lengtes ontstaan. Dit wordt microsatelliet 
instabiliteit genoemd. Tumoren van Lynch syndroom patiënten worden gekenmerkt door 
Appendix 
184 
microsatelliet instabiliteit en het verlies van eiwit van de mismatch herstelgenen bij 
kleuring van de tumor (immunohistochemie). Daarom kan analyse van microsatelliet 
instabiliteit en immunohistochemie worden ingezet als screening om patiënten te 
identificeren die mogelijk Lynch syndroom hebben. 
 
Eerdere richtlijnen adviseerden moleculaire screening voor Lynch syndroom bij alle 
darmkanker patiënten tot 50 jaar. In hoofdstuk 4 en 5 berekenden we de kosten-
effectiviteit van routinematige screening op Lynch syndroom bij alle patiënten met 
darmkanker of baarmoederkanker tot 70 jaar. De extra kosten voor het verleggen van de 
leeftijdsgrens van 50 naar 70 jaar bij deze patiënten bleef <€13.000 per gewonnen 
levensjaar. Dit valt ruim binnen de grenzen voor kosteneffectiviteit (<€40.000 per 
gewonnen levensjaar). De huidige internationale richtlijnen adviseren routinematige 
screening op Lynch syndroom middels analyse van microsatelliet instabiliteit en/of 
immunohistochemie bij alle patiënten met darmkanker of baarmoederkanker tot 70 jaar. 
 
Wanneer bij een patiënt met darmkanker of baarmoederkanker Lynch syndroom wordt 
vastgesteld, hebben met name gezonde familieleden van deze patiënt die dezelfde 
mutatie dragen, hier baat van, omdat het ontstaan van kanker bij hen nog kan worden 
voorkomen. Het identificeren van Lynch syndroom bij patiënten met adenomen (een 
voorstadium van darmkanker) zou dezelfde hoge winst voor patiënten zelf betekenen. 
Echter in hoofdstuk 6 werd bij routinematige screening op Lynch syndroom bij alle 
patiënten met gevorderde adenomen in het bevolkingsonderzoek naar darmkanker geen 
enkele patiënt met Lynch syndroom geïdentificeerd. Routinematige screening van alle 
adenomen lijkt daarom niet zinvol. Screening van een deel van deze patiënten, zoals 
jongere patiënten, zou wel effectief kunnen zijn. 
 
Varianten van onbekende klinische betekenis  
De definitieve diagnose Lynch syndroom wordt gesteld wanneer een ziekteverwekkende 
mutatie in een van de mismatch herstelgenen MLH1, MSH2, MSH6 or PMS2, of verlies 
van een stuk DNA aan de achterkant van het EPCAM-gen wordt aangetoond. In sommige 
gevallen wordt een DNA-variant gevonden waarvan we niet zeker weten of het tot Lynch 
syndroom kan leiden, waardoor de diagnose onzeker blijft. De juiste classificering van 
varianten in de mismatch herstelgenen is zeer belangrijk, vanwege de implicaties die dit 
heeft voor het controleadvies. 
 
Hoofstuk 7 en 8 omvat de evaluatie van een test om varianten, waarvan we niet weten 
of ze ziekteverwekkend zijn, in de mismatch herstelgenen te classificeren. We hebben de 
analyse gedaan op 26 varianten in MLH1, MSH2 en MSH6. Zeven varianten in MLH1, vijf 
varianten in MSH2 en drie varianten in MSH6 waren ziekteverwekkend volgens de 
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functionele test. In de meeste gevallen kwam dit goed overeen met klinische data, 
predictie programma’s en de resultaten van andere functionele testen. 
 
Surveillance van Lynch syndroom patiënten  
Het doel van de identificatie van Lynch syndroom patiënten is om hen te informeren 
over het verhoogde risico op kanker en middels periodieke controles het ontstaan van 
kanker en de sterfte verlagen. Periodieke controles middels colonoscopie elke 1-2 jaar 
wordt geadviseerd vanaf 25-jarige leeftijd. Hoewel het kankerrisico bij Lynch syndroom 
patiënten sterk afhankelijk is van het betrokken gen, wordt alle patiënten momenteel 
dezelfde controles aangeboden. Daarom wordt in hoofdstuk 9 de opbrengst van deze 
colonoscopie controles geëvalueerd voor MLH1, MSH2, MSH6 en PMS2 mutatiedragers. 
 
Bij de meeste colonoscopieën werden geen adenomen (voorstadium van darmkanker) of 
darmkanker gevonden en er waren geen significante verschillen in het aantal adenomen 
dat werd gevonden tussen de verschillende patiëntengroepen. Echter het risico op 
gevorderde neoplasie (een gevorderd adenoom of darmkanker) liep voor MSH6 
mutatiedragers langzamer op dan voor de andere groepen. Op basis van deze 
langzamere progressie en het feit dat geen van de 121 MSH6 mutatiedragers 
darmkanker ontwikkelden gedurende de studieperiode, behoeven MSH6 mutatiedragers 
waarschijnlijk minder frequente controles dan mensen met een mutatie in MLH1 of 
MSH2. Het interval tussen colonoscopieën zou daarom mogelijk verlengd kunnen 
worden tot drie jaar voor MSH6 mutatiedragers. Vanwege het kleine aantal PMS2 
mutatiedragers konden voor deze groep geen sterke conclusies worden getrokken, maar 
gebaseerd op het lagere kankerrisico bij PMS2 mutaties is minder frequente controle ook 
bij deze patiënten waarschijnlijk voldoende. 
 
Ten slotte worden in hoofdstuk 10 de resultaten van dit proefschrift besproken in relatie 
tot de huidige richtlijnen en de klinische praktijk. 
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Een aantal personen wil ik hier specifiek noemen. 
 
Allereerst mijn promotoren, prof. dr. R.M.W. Hofstra en prof. dr. M.J. Bruno. Dank voor 
jullie kritische blik. Beste Robert, na een overleg kon ik steeds met nieuwe ideeën en 
frisse moed aan de slag, dank voor de begeleiding en de motiverende besprekingen. 
Beste Marco, dank voor de altijd snelle reacties met waardevolle suggesties voor 
abstracts en manuscripten. 
 
Mijn beide copromotoren, dr. A. Wagner en dr. M.C.W. Spaander. Dank voor jullie 
vertrouwen in mij en jullie enthousiasme voor wetenschappelijk onderzoek met oog voor 
de patiëntenzorg. Anja, als iemand me zou vragen om een empathische dokter uit te 
tekenen, zou ik direct naar jou verwijzen. Ik heb bewondering voor de manier waarop jij 
je inzet voor je patiënten en heb daarnaast ook veel geleerd van jouw relativerende 
opmerkingen. Manon, het is onvoorstelbaar hoe jij de begeleiding van een grote groep 
promovendi combineert met al je andere werkzaamheden en dat met enorme 
betrokkenheid en zonder enige concessie wat betreft kwaliteit. 
 
De leden van de leescommissie dank ik voor de beoordeling van dit proefschrift. Mijn 
dank gaat ook uit naar de volledige promotiecommissie voor hun bereidheid om met mij 
van gedachten te wisselen over de inhoud van dit proefschrift. 
  
Uiteraard hebben veel mensen een bijdrage geleverd aan de hoofdstukken uit dit 
proefschrift. Alle coauteurs dank ik voor hun bijdrage. In het bijzonder wil ik Winand 
Dinjens en Erik Jan Dubbink danken voor de fijne samenwerking, altijd oprechte 
interesse en jullie enthousiasme voor jullie vakgebied. Hein te Riele en Hellen 
Houlleberghs dank ik voor de kans die ik kreeg om in het lab zelf diverse VUS te testen. 
Hellen, dank voor de fijne samenwerking, de reistijd naar Amsterdam was het zeker 
waard. Ewout Steyerberg dank ik voor de overleggen rondom de kosten-
effectiviteitstudies en de predictiemodellen studie. 
 
Mijn voorgangers hebben veel werk verzet om data van patiënten te verzamelen die in 
de hoofdstukken van dit proefschrift gebruikt kon worden. Mijn dank aan ieder die aan 
de EMDL database en de LIMO studies heeft bijgedragen. 
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De collega’s van de MDL dank ik voor de gezellige congressen. In het bijzonder Ingrid, ik 
ben blij dat je vandaag als paranimf aan mijn zijde wil staan en kijk uit naar jouw 
promotie binnenkort. 
 
Gedurende mijn promotietraject heb ik verschillende werkplekken op de 20e verdieping 
gehad. Dank aan de genetisch consulenten en het datateam voor het warme welkom op 
hun kamer. En uiteraard dank aan de arts-assistenten met wie ik in de loop der tijd een 
kamer deelde. In 2016 ben ik gestart als ANIOS en inmiddels AIOS bij de counseling. De 
samenwerking met de verschillende Klinisch Genetici en de leuke groep arts-assistenten 
zorgen ervoor dat ik steeds met plezier aan het werk ga. Ik ben ontzettend blij dat ik de 
komende jaren mijn opleiding in Rotterdam mag volgen. 
 
Ook buiten het werk zijn er natuurlijk veel mensen die op andere manieren bijdragen aan 
een promotietraject. Een aantal mensen wil ik hierbij specifiek noemen. Mijn jaarclub, 
waarin ik inmiddels alweer de derde ben die een promotietraject afsluit en in het 
bijzonder Sonja voor de welkome koffie/theemomenten in het EMC. Ten tweede 
natuurlijk Wendy. We zijn al jaren vriendinnen en in de afgelopen maanden had ik veel 
aan jouw organisatietalent. Ik hoop dat er nog veel etentjes volgen waarbij we uren over 
het bestellen kunnen doen. Dan mijn lieve schoonfamilie. Dank voor jullie interesse. Ik 
voel me altijd welkom bij jullie en bewonder jullie doorzettingsvermogen enorm. 
 
Mijn grote broers René en Erik, dank voor al jullie support door de jaren heen. René, jij 
vormt met Daphne, Pelle en Rasmus een prachtig gezin. Een dagje Scheveningen kan wel 
eens het beste medicijn tegen werkstress zijn. Nu dit boek af is, zullen we weer vaker 
afspreken! Erik, dank voor de technische ondersteuning bij alle computerproblemen 
tijdens mijn promotietraject. Ik ken niemand die zoveel rust uit kan stralen als jij. Dank 
dat je tijdens mijn promotie als paranimf naast me wil staan. 
 
Mama en papa. Jullie hebben ons altijd gestimuleerd om ons hart te volgen en de volle 
100% te geven. Ik kan jullie nooit genoeg bedanken voor het warme nest waarin ik 
mocht opgroeien. Jullie lijken een onbegrensd vertrouwen in mijn kunnen te hebben en 
ik hoop dat ik daar ook maar de helft van kan waarmaken. Allebei zijn jullie harde 
werkers. Ik wens jullie, nu jullie aan het pensioen samen beginnen, een heleboel gezonde 
jaren vol ontspanning toe. 
 
Tot slot, lieve Stefan, dank voor je geduld tijdens de afronding van mijn promotie en het 
nakijken van alle punten en komma’s. Vanaf het begin van mijn studietijd was jij er bij. 
Jouw humor en relativeringsvermogen zijn onbetaalbaar. Ik kijk uit naar alles wat we 
samen nog gaan ondernemen. #Happiness. 
  
  
 
 
